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Abstract
Anhedonia, the lost of interest or pleasure in normally enjoyable activities, is a core clinical feature of major
depressive disorder (MDD). Although the term encompasses both consummatory and appetitive
components, empirical findings suggest that anhedonia is more closely associated with deficits in motivational
processing as opposed to alterations in hedonic valuation of rewards. A growing body of evidence points to a
role for the mesolimbic dopamine (DA) system in the etiology of motivational deficits. However, the
neurobiological mechanisms underlying the manifestation of anhedonic behavior are still not well
understood. Given the frequent presentation of anhedonia in stress-related psychiatric disorders, we
hypothesized that exposure to stressors disrupts brain signaling pathways that would typically facilitate reward
processing. The experiments in this thesis utilized the novelty-induced hypophagia (NIH) test, a motivational
conflict paradigm, to examine the effects of stress on neural processes associated with the attribution of
incentive salience to salient stimuli. Using in vivo microdialysis, we assessed the role of nucleus accumbens
(NAc) DA transmission in mediating conditioned approach behavior for food reward, and established that
stress exposure blunts NAc DA response to palatable food and reduces incentive salience for the reward, as
defined by increased latency to approach. Pretreatment with the mixed action opioid drug buprenorphine
prevented the behavioral and neurochemical effects of stress in this paradigm, implying a role for the brain
opioid system in mitigating the negative effects of stress on incentive behavior. Using a combination of genetic
and pharmacological tools, the role of individual opioid receptors in restoring approach behavior suppressed
by stress in the NIH test was next dissected. These studies identified the mu opioid receptor as a critical
mediator of approach behavior and a potential pharmacological target for alleviating prodepressive behaviors
during stress. Lastly, the interaction between elevated stress hormones and treatment with the selective
serotonin reuptake inhibitor fluoxetine, a commonly used antidepressant, was investigated on incentive
behavior in the NIH paradigm. We found that exogenous corticosterone exposure facilitated reduced
approach behavior caused by exposure to chronic fluoxetine in C57BL/6 mice. Thus, exposure to stress
hormones enabled fluoxetine to produce a behavior modeling a therapeutic response in a strain of mice that
are otherwise insensitive to this antidepressant drug. Collectively, these findings further expand our
understanding of the mechanisms underlying stress-induced affective behavior and antidepressant drug
treatments.
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ABSTRACT 
 
 
NEUROPHARMACOLOGICAL MECHANISMS UNDERLYING  
INCENTIVE SALIENCE AND STRESS 
 
Shivon A. Robinson 
Irwin Lucki 
 
Anhedonia, the lost of interest or pleasure in normally enjoyable activities, is a core 
clinical feature of major depressive disorder (MDD). Although the term encompasses 
both consummatory and appetitive components, empirical findings suggest that 
anhedonia is more closely associated with deficits in motivational processing as 
opposed to alterations in hedonic valuation of rewards.  A growing body of evidence 
points to a role for the mesolimbic dopamine (DA) system in the etiology of motivational 
deficits. However, the neurobiological mechanisms underlying the manifestation of 
anhedonic behavior are still not well understood. Given the frequent presentation of 
anhedonia in stress-related psychiatric disorders, we hypothesized that exposure to 
stressors disrupts brain signaling pathways that would typically facilitate reward 
processing.  The experiments in this thesis utilized the novelty-induced hypophagia 
(NIH) test, a motivational conflict paradigm, to examine the effects of stress on neural 
processes associated with the attribution of incentive salience to salient stimuli. Using in 
vivo microdialysis, we assessed the role of nucleus accumbens (NAc) DA transmission 
in mediating conditioned approach behavior for food reward, and established that stress 
exposure blunts NAc DA response to palatable food and reduces incentive salience for 
the reward, as defined by increased latency to approach. Pretreatment with the mixed 
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action opioid drug buprenorphine prevented the behavioral and neurochemical effects of 
stress in this paradigm, implying a role for the brain opioid system in mitigating the 
negative effects of stress on incentive behavior. Using a combination of genetic and 
pharmacological tools, the role of individual opioid receptors in restoring approach 
behavior suppressed by stress in the NIH test was next dissected. These studies 
identified the mu opioid receptor as a critical mediator of approach behavior and a 
potential pharmacological target for alleviating prodepressive behaviors during stress. 
Lastly, the interaction between elevated stress hormones and treatment with the 
selective serotonin reuptake inhibitor fluoxetine, a commonly used antidepressant, was 
investigated on incentive behavior in the NIH paradigm. We found that exogenous 
corticosterone exposure facilitated reduced approach behavior caused by exposure to 
chronic fluoxetine in C57BL/6 mice. Thus, exposure to stress hormones enabled 
fluoxetine to produce a behavior modeling a therapeutic response in a strain of mice that 
are otherwise insensitive to this antidepressant drug. Collectively, these findings further 
expand our understanding of the mechanisms underlying stress-induced affective 
behavior and antidepressant drug treatments.  
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Overview of depression 
  
Major Depressive Disorder (MDD) is one of the most common forms of psychiatric 
illness existing today, with a lifetime prevalence of 17% in the US and 4% worldwide 
(Kessler et al., 2003). MDD is characterized by the presence of at least one of two major 
symptoms, depressed mood or the lost of interest or pleasure in daily activities, in 
addition to at least five secondary symptoms for a period of two or more weeks (DSM-V-
TR, American Psychiatric Association).  Secondary symptoms of MDD span a wide 
range of somatic, cognitive, and emotional deficits, including psychomotor agitation or 
retardation, diminished ability to concentrate, and feelings of worthlessness or excessive 
guilt. This combination of symptomology is incredibly disruptive to daily functioning and 
is consistently associated with impaired productivity and reduced job retention (Beck et 
al., 2011). The economic impact of lost productivity due to depression is estimated to 
amount to over $30 billion per year in the United States alone (Stewart et al., 2003).  The 
chronicity of depression further adds to the debilitating nature of this condition. As many 
as 50% of people who recover from a depressive episode will experience an additional 
episode, typically within five years of the initial episode (Belsher and Costello, 1988; 
Kupfer and Frank, 2001; Burcusa and Iacono, 2007). Moreover, individuals diagnosed 
with MDD are at increased risk to develop other serious medical illnesses, such as heart 
disease (Lett et al., 2004) and stroke (Williams et al., 2004). In terms of years lost to ill-
health or early death, MDD is considered one of the most disabling medical conditions 
and is predicted to be among the top three contributors to the worldwide burden of 
disease by 2030 (Mathers and Loncar, 2006).   
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 Despite the availability of antidepressant medications, MDD continues to be a 
challenging disorder to treat. Results from the Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) study, the largest longitudinal randomized study of 
antidepressant efficacy to date, showed that the frequently used selective serotonin 
reuptake inhibitor (SSRI) citalopram produced a remission rate of around 30% (Trivedi et 
al., 2006). Furthermore, many of the participants who achieved remission did so after 8 
weeks of treatment or later. Approximately 30-60% of depressed individuals do not 
respond to the first antidepressant prescribed and an estimated 15-30% fail to respond 
to multiple treatments and are considered treatment-resistant (Cain, 2007; Berlim et al., 
2008). These alarming statistics highlight the importance of advancing our 
understanding of the biological mechanisms underlying depression to develop more 
efficacious and faster-acting therapies for the treatment of MDD. 	  
Anhedonia as a depressive endophenotype 
 
The investigation into the neurobiological mechanisms that govern the onset and 
maintenance of depression has been hindered in part by the broad diagnostic 
characterization of MDD. The currently used system of classification criteria for MDD 
encompasses a wide range of symptoms that differ in severity, onset, and recurrence 
(DSM-V-TR, American Psychiatric Association) and are likely mediated by different, 
though possibly related, physiological processes (Charney and Manji, 2004). For 
example, patients diagnosed with depression may either sleep more than normal or 
suffer from insomnia and report their appetite for food is greater or less than normal. The 
heterogeneous nature of MDD, as it is presently defined, severely limits the likelihood of 
discovering an etiological course consistent between all depressed individuals. A more 
appropriate strategy may be to focus research efforts on endophenotypes, narrowly 
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defined behavioral dimensions and biological measures that span traditional diagnostic 
criteria. The recently described research domain criterion (RDoC) framework 
emphasizes deconstruction of psychiatric syndromes into fundamental neurobiological 
components that can then be mapped onto genetic, molecular, cellular, and behavioral 
processes (Cuthbert, 2014)  This approach allows for identification of the “downstream” 
mechanisms underlying specific clinical phenotypes and the “upstream” consequences 
of physiological processes (Hasler et al., 2004). The endophenotype system operates on 
the assumption that the biological processes regulating the manifestation of individual 
endophenotypes are fewer and less multifaceted than those of the psychiatric entity as a 
whole. Whether or not this is the case is yet to be determined. Nevertheless, closer 
examination into endophenotypes of depression has the potential to yield important 
findings and implications for the classification and subsequent treatment of depressive 
disorders (Berghorst and Pizzagalli, 2010).  
 The evaluation of endophenotypes is based on several criteria including 
heritability, specificity, and biological and clinical plausibility (Tsuang et al., 1993). Of the 
many psychopathological endophenotypes associated with depression (cognitive 
deficits, REM sleep abnormalities, and psychomotor changes to name a few), impaired 
reward function has the most compelling empirical evidence and broadest applicability 
(Hasler et al., 2004; Pizzagalli et al., 2005). Anhedonia, clinically defined as diminished 
interest or pleasure in response to stimuli that were previously perceived as rewarding in 
a premorbid state, is one of two required symptoms for the diagnosis of MDD (DSM-V-
TR, American Psychiatric Association). Approximately 37% of individuals with 
depression experience clinically significant anhedonia (Pelizza and Ferrari, 2009).. 
Blunted reward sensitivity and diminished motivational drive are strong predictors for the 
diagnosis of MDD (Zimmerman et al., 2006; Treadway and Zald, 2013; Pizzagalli, 2014). 
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Moreover, clinical studies indicate a familial association and heritability of anhedonic 
endophenotypes in depression (Bogdan and Pizzagalli, 2009; Sieradzka et al., 2015). 
Although hedonic deficits are commonly observed in other psychiatric disorders, such as 
schizophrenia and post-traumatic stress disorder, anhedonia within these illnesses is 
often associated with the presentation of depressive-like symptoms (Loas et al., 1999; 
Kashdan et al., 2006; Volkow et al., 2011). In regards to the biological underpinnings of 
anhedonia, multiple lines of evidence from both clinical and preclinical sources support a 
role for the brain reward system. 
Reward sensitivity and processing in anhedonia 
 
The most well-characterized reward circuit of the brain is comprised of dopaminergic 
neurons originating in the ventral tegmental area (VTA) that project to and innervate 
several limbic and cortical structures regions, including the nucleus accumbens (NAc), 
amygdala, hippocampus, and medial prefrontal cortex (mPFC). These structures are 
interconnected through reciprocal glutamatergic connections that are further modulated 
by GABAergic interneurons. Notably, dopaminergic projections from the VTA to the NAc 
have been shown to mediate the reinforcing properties of both natural rewards and 
drugs of abuse. Presentation of a rewarding stimulus produces phasic elevation of 
dopamine (DA) levels in the NAc, whereas depletion of DA in this region reduces reward 
responsiveness and reward-seeking behavior (Ikemoto and Panksepp, 1999). DA acts 
primarily on two subfamilies of G-protein coupled receptors (GPCRs) known as D1-like 
and D2-like receptors (Cooper et al., 2003). Stimulation of D1-like receptors increases 
adenylate cyclase activity, while stimulation of D2-like receptors decreases adenylate 
cyclase activity (Surmeier et al., 2007). Activation of DA receptors within the striatum 
modulates the sensitivity of medium spiny neurons to excitatory glutamatergic input from 
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corticolimbic structures (Hernandez-Lopez et al., 2000; Surmeier et al., 2007).   
 The proposed functional role of the midbrain DA system in reward processing 
has deviated over time. Early studies suggested that DA directly produced the hedonic 
impact, or “liking”, of a pleasant stimulus (Wise, 1985; Koob and Le Moal, 1997). This 
concept was later challenged by taste reactivity studies which demonstrated that 
depletion of DA in rodent forebrain and striatal regions does not alter hedonic impact to 
rewards, suggesting that mesocorticolimbic DA activity is not necessary for “liking” 
(Berridge et al., 1989; Berridge, 2000). Seminal work conducted by Schultz et al. (1997) 
established a role for DA in the learning processes associated with reward response. In 
these studies, monkeys presented with appetitive stimuli, but not aversive, exhibited 
phasic activation of midbrain neurons. Repeated pairings of environmental cues with a 
rewarding stimulus shifted the temporal onset of phasic activation from the time of 
reward delivery to the time of cue presentation. Moreover, the basal firing of DA neurons 
was distinctly suppressed in trials that the reward was not presented after presentation 
of the conditioned cue. These observations gave rise to the reward prediction error 
hypothesis, which posits that DA encodes the discrepancy between predicted and 
experienced reward, thus regulating reinforcement-dependent learning (Schultz et al., 
1997; Hyman et al., 2006; Wise, 2008; Glimcher, 2011). Building upon these 
electrophysiological observations, Berridge and Robinson (1998) proposed incentive 
salience theory, which describes a role for DA in mediating the learned reward 
associations that attribute motivational “wanting”, but not “liking”, to a previously neutral 
stimulus (Berridge, 2012). Indeed, several studies have demonstrated dissociation 
between motivational behavior and hedonic valuation in response to rewarding stimuli.  
For example, highly rewarding drugs of abuse have repeatedly been shown to induce 
conditioned taste aversion in rodents at doses that would be readily self-administered 
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(Berger, 1972; Cappell and Le Blanc, 1973; Cappell et al., 1973; Wise et al., 1976; White 
et al., 1977). Although, more recent studies have argued that avoidance of cues 
associated with drugs of abuse is independent of taste aversion, and may instead reflect 
conditioned fear (Parker, 2003).  On the other hand, DA antagonists and NAc DA 
depletion have been shown to distinctly suppress effort-related behavioral responding for 
food reward without diminishing food consumption in low-effort conditions (Aberman and 
Salamone, 1999; Salamone et al., 2002). Thus, mesolimbic DA activity within the NAc is 
likely involved in the effort-based and goal-directed behavior that underlies motivational 
“wanting” of an attractive stimulus.       
 Diagnostic assessments of anhedonia in depressed individuals have traditionally 
emphasized the aspect of “loss of pleasure” (Treadway and Zald, 2013). Although, MDD 
patients often report diminished general positive affect and reduced intensity of 
emotional experiences (Germans and Kring, 2000; Naragon-Gainey et al., 2009), 
several studies indicate that individuals presenting with anhedonia do not differ from 
healthy controls in perceiving the pleasantness of an emotionally salient stimulus 
(Berenbaum and Oltmans, 1992; Burbridge and Barch, 2007; Etain et al., 2007; Sherdell 
et al., 2012). Instead, clinical evidence suggests that anhedonia in depression is 
characterized primarily by deficits in affective processing that may underlie reduced 
motivational drive for reward (Pizzagalli, 2014). Laboratory studies utilizing 
reinforcement paradigms demonstrate that MDD patients fail to develop a response bias 
towards more rewarding stimuli (Pizzagalli et al., 2005; Pizzagalli et al., 2008), an effect 
that has been shown to be associated with striatal function in monkeys (Lauwereyns et 
al., 2002). Neuroimaging studies have linked MDD to reduced grey matter volume within 
striatal regions (Kim et al., 2008; Matsuo et al., 2008; Pizzagalli et al., 2008; Wacker et 
al., 2009) and diminished activation of the ventral striatum to anticipation of rewards 
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(Forbes, 2011; Smoski et al., 2011), reward prediction errors (Steele et al., 2007; Kumar 
et al., 2008), and receipt of reward (McCabe et al., 2009; Pizzagalli et al., 2009; Smoski 
et al., 2009; Wacker et al., 2009). Moreover, severity of anhedonic symptoms is 
positively correlated with reduced ventral striatum response to rewarding stimuli 
(Keedwell et al., 2005; Epstein et al., 2006). Altered striatal activity in MDD may be a 
result of generally reduced DA activity. MDD patients exhibit lower levels of 
cerebrospinal homovanilic acid, the primary metabolite of DA, signifying reduced basal 
levels of DA in depression (Lambert et al., 2000; Mitani et al., 2006). Furthermore, 
positron emission topography imaging studies report reduced DA transporter binding in 
the striatum of depressed patients with anhedonic symptoms (Sarchiapone et al., 2006). 
Altogether, these findings suggest a link between alterations in mesocorticolimbic DA 
functioning and impaired reward processing in anhedonia.   
Interaction of brain stress and reward systems in depression 
 
A substantial body of evidence supports a pathophysiological role of stress in 
depression. Approximately 80% of depressive episodes are reported to be preceded by 
a stressful life event (Mazure, 1998; Hammen, 2005). However, prospective longitudinal 
studies have also found exposure to chronic stressors (i.e. persisting for more than 12 
months) rather than acute stressful episodes to have a significant influence on the onset 
and course of depression (Caspi et al., 2003; Harkness and Monroe, 2006). Exposure to 
chronic stress is associated with more frequent recurrences (Lethbridge and Allen, 
2008), increased resistance to treatment (Amital et al., 2008), and more severe 
depressive symptoms (Leskela et al., 2006). Interestingly, the association between 
stress and depression weakens after multiple depressive episodes (Kendler et al., 
1998), suggesting that factors aside from stress reactivity are more closely associated 
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with recurrent rather than initial depressive episodes. 
 Stress is also strongly associated with the manifestation of anhedonic behavior. 
Acute stress has been shown to impair reward responsiveness within healthy 
populations, particularly in individuals who exhibited greater cortisol reactivity to the 
stressor (Berghorst et al., 2013) or self-reported higher levels of anhedonia (Bogdan and 
Pizzagalli, 2006). Moreover, both acute and chronic stressors are reported to produce 
hedonic blunting, predominantly in individuals with a family history of depression 
(Berenbaum and Connelly, 1993; Al'absi et al., 2012). Conversely, pronounced 
anhedonic symptoms are correlated with increased sensitivity to stress (Horan et al., 
2007). These observations indicate an interaction between brain stress and reward 
systems in the emergence of depressive phenotypes. 
Hypothalamic-pituitary-adrenal (HPA) axis 
The hypothalamic-pituitary-adrenal (HPA) axis is an integral component of the body’s 
homeostatic and stress response system. Exposure to either a physical or psychological 
stressor facilitates synthesis and secretion of corticotrophin-releasing factor (CRF) from 
the hypothalamus. CRF stimulates the secretion of adrenocorticotropic hormone (ACTH) 
from the pituitary gland, which in turn triggers the adrenal glands to release 
glucocorticoid hormones, commonly referred to as cortisol in humans and corticosterone 
(CORT) in rodents (Sapolsky et al., 2000). Glucocorticoids mobilize the body’s energy 
stores and regulate a variety of cardiovascular, metabolic, and immunological functions 
to effectively prepare the body to respond to a stressor and facilitate recovery to 
homeostasis (Kadmiel and Cidlowski, 2013). Over a longer time scale, glucocorticoids 
regulate the expression of genes and promote memory formation, effects thought to 
mediate adaptive modulations to the system for future events (de Kloet et al., 2005; 
10	  
	  
Groeneweg et al., 2011).       
 Glucocorticoids enact their effects through molecular events that trigger genomic 
and non-genomic mechanisms that involve the dual activation of intracellular 
mineralocorticoid (MR) and glucocorticoid receptors (GR), collectively referred to as 
corticosteroid receptors. Once diffused through the cellular membrane, glucocorticoids 
bind to the receptor complex and translocate into the nucleus to act on DNA response 
elements to activate gene transcription (Ringold, 1985). Alternatively, the receptor 
complex can repress expression of genes by inhibiting other transcription factors from 
binding to their target genes (De Bosscher et al., 2003). More recently, a non-classical 
corticosteroid pathway involving membrane bound GRs and MRs has been shown to 
mediate the rapid non-genomic mechanisms of stress response (Tasker et al., 2006). 
 Within the central nervous system, GRs and MRs differ in both their affinity for 
glucocorticoids and regional pattern of expression. MRs exhibit a higher affinity for 
glucocorticoids and regulate basal HPA tone, whereas GRs are only activated during 
conditions involving high circulating levels of CORT and facilitate termination of the 
stress response (De Kloet et al., 1998). GRs are widely distributed throughout the brain, 
but exhibit high levels of expression in the hypothalamus and corticolimbic structures, 
including the hippocampus, prefrontal cortex, and amygdala.  MRs, on the other hand, 
are less ubiquitous in the brain, but are highly expressed in the hippocampus (Young et 
al., 2003; Joels et al., 2012). Elevated circulating levels of glucocorticoids serve as a 
negative feedback signal to the HPA axis by binding to GRs at the level of the 
hypothalamus and pituitary to inhibit further secretion of CRF and ACTH (Miller et al., 
1992). The HPA axis also receives strong regulatory inputs from the hippocampus.  
Activation of corticosteroid receptors on hippocampal neurons signal for the termination 
of HPA axis activity (Sapolsky et al., 1984; Jacobson and Sapolsky, 1991).   
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 Under normal conditions, glucocorticoids serve to facilitate the physiological 
adaptations required to appropriately respond to stressors. Excessive activation of the 
HPA axis, however, is thought to contribute to the onset of depressive symptoms. A 
substantial proportion of MDD patients demonstrate signs of HPA axis dysfunction, as 
evidenced by flattening of cortisol diurnal rhythms, augmented circulating concentrations 
of cortisol and CRF (Nemeroff et al., 1984) and insensitivity to dexamethasone, an 
exogenous steroid that suppresses cortisol in healthy controls (Holsboer et al., 1987). 
Both the expression and function of GRs are significantly reduced in depressed 
individuals (López et al., 1998; Pariante, 2004). Moreover, early-life stress exposure is 
predictive of structural reductions in regions involved in regulation of the HPA axis 
(Sahay and Hen, 2007; Treadway et al., 2009), indicating that HPA axis dysregulation in 
depression likely occurs via diminished inhibitory feedback signals.  Notably, MDD is 
consistently associated with reductions in hippocampal volume (Campbell et al., 2004; 
Videbech et al., 2004). In addition to its role in glucocorticoid inhibitory feedback 
mechanisms, the hippocampus is also a key mediator of cognitive and emotional 
processes. Thus, altered hippocampal neuronal activity may contribute to the 
psychopathologies of depression.         
 Outside of the HPA axis, CRF-containing neurons and CRF receptors are widely 
distributed throughout brain regions implicated in stress response (Swanson et al., 1983; 
Sakanaka et al., 1987; Griebel and Holsboer, 2012), suggesting that CRF can act 
directly at these regions independent of HPA axis activation (Koob et al., 1993; 
Dautzenberg and Hauger, 2002). . The effects of CRF are mediated through activation of 
two subfamilies of GPCRs, CRF-R1 and CRF-R2, though CRF shows greater binding 
affinity for CRF-R1 (Dautzenberg and Hauger, 2002). Exogenous administration of CRF 
mimics many of the behavioral and autonomic effects of acute stress exposure (Dunn 
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and Berridge, 1987), and has been shown to induce depressive and anxiety-like 
behaviors in rodents (Britton et al., 1982; Owens and Nemeroff, 1991; Liang et al., 1992; 
Swiergiel et al., 2008). Notably, antagonism of CRF receptors attenuates many of the 
affective behavioral responses to stress (Britton et al., 1986; Heinrichs et al., 1994; Bale 
and Vale, 2004). Hypersecretion of CRF has been implemented in the onset of 
depressive disorders. MDD patients exhibit elevated cerebrospinal fluid levels of CRF 
(Nemeroff et al., 1984) and enhanced neuroendocrine response to the combined 
dexamethasone/CRF test  (Steckler et al., 1999) that is normalized after successful 
antidepressant treatment (Heuser et al., 1998; Ising et al., 2005). Additionally, port-
mortem studies have revealed increased CRF expression and reduced binding in the 
brains of depressed individuals. (Nemeroff et al., 1988; Purba et al., 1996).  
Effects of Stress on Mesocorticolimbic Dopaminergic Pathways 
Brain stress response systems interact with the midbrain DA system to produce complex 
state-dependent responses to aversive stimuli (Cabib and Puglisi-Allegra, 2012). 
Corticosteroid receptors and CRF receptors are expressed throughout the 
mesocorticolimbic system, specifically in the prefrontal cortex, amygdala, NAc, and VTA 
(Harfstrand et al., 1986; Van Pett et al., 2000; Dautzenberg and Hauger, 2002; Butts et 
al., 2011; Hensleigh and Pritchard, 2013). CRF in the VTA reduces operant responding 
for food reward and attenuates NAc DA release to food reward (Wanat et al., 2013). 
Electrophysiological studies report inhibition of VTA DA neurons in response to stress 
(Ungless et al., 2004), however distinct anatomical regions within the VTA have been 
shown to contain DA neurons that differ in their molecular properties and response to 
aversive versus rewarding stimuli. For example, DA neurons in the dorsal VTA are 
inhibited by acute stress, whereas DA neurons in the ventral VTA are excited by 
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aversive footshocks (Brischoux et al., 2008). Moreover, aversive stimuli selectively 
modify synapses projecting to the mPFC, whereas rewarding stimuli modifies synapses 
on DA cells projecting to NAc medial shell (Lammel et al., 2011). Additionally, 
GABAergic neurons in the rostromedial tegmental nucleus (RMTg) project to VTA DA 
neurons and are selectively activated in response to stress (Jhou et al., 2009). Thus, 
aversive inputs from various brain regions implicated in stress response may converge 
onto the RMTg to inhibit DA transmission in the NAc.  
 Several studies have reported robust DA release in the mPFC following acute 
stress (Imperato et al., 1989) or acute administration of CORT (Piazza et al., 1996; Butts 
et al., 2011).  Chronic administration of exogenous CORT flattens glucocorticoid rhythm 
and enhances basal and depolarization evoked DA release in the mPFC in a GR-
dependent manner (Ago et al., 2008; Minton et al., 2009). Mesocortical DA neurons 
exert top-down control over striatal DA release (Deutch and Roth, 1990; King et al., 
1997; Ventura et al., 2002).  Therefore, stress-induced potentiation of mPFC DA activity 
may facilitate blunted DA release in mesolimbic pathways. Additionally, NAc 
responsiveness to excitatory input from the mPFC has been shown to be regulated by 
the hippocampus (O'Donnell and Grace, 1995). Hence, motivational states are likely 
influenced by glucocorticoid-mediated alteration of hippocampal function. Interestingly, 
stress-induced stimulation of mesoaccumbens DA release is associated with short-
lasting or controllable aversive experiences (Abercrombie et al., 1989; Ventura et al., 
2002; Cabib and Puglisi-Allegra, 2012), whereas exposure to chronic or uncontrollable 
stressors selectively activates the HPA axis (De Boer et al., 1989) and promotes 
inhibition of mesoaccumbens DA (Puglisi-Allegra et al., 1991; Imperato et al., 1992; 
Rossetti et al., 1993; Cabib and Puglisi-Allegra, 2012). Reduced mesoaccumbens DA 
activity after chronic or uncontrollable stress is posited to contribute to coping failure and 
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the development of behavioral despair (Cabib and Puglisi-Allegra, 2012). This holds 
particular relevance for the etiology of psychiatric disease states seeing as exposure to 
chronic stressors perceived as uncontrollable or unresolvable is more associated with 
depressive behavior (Kendler et al., 2003).  
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FIGURE 1.1  
 
 
VTA-NAc reward circuit and HPA axis. A simplified schematic of the major 
connections within the mesocorticolimbic dopamine system and hypothalamic-pituitary-
adrenal axis. DA neurons originating from the VTA project to and innervate subcortical 
and cortical regions. This pathway is further modulated by reciprocal glutamatergic and 
GABAergic signaling. Exposure to stress activates secretion of CRF from the PVN, 
which stimulates secretion of ACTH from the pituitary, which in turn triggers release of 
CORT from the adrenals. CORT serves as a negative feedback signal at the level of the 
pituitary and PVN. CRF and CORT act on brain regions that overlap with brain reward 
circuitry to modulate dopamine response to both rewarding and aversive stimuli. ACTH, 
adrenocorticotropic hormone; AMY, amygdala; CORT, corticosterone; CRF, 
corticotropin-releasing factor; HIPP, hippocampus; LHb, lateral habenula; LDTg, lateral 
dorsal tegmentum; NAc, nucleus accumbens; PFC, prefrontal cortex; PVN, 
paraventricular nucleus of the hypothalamus; RMTg, rostromedial tegmentum; VTA, 
ventral tegmental area.  
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Opioid System                   
In addition to its well-established role in nociception and analgesia (Dickenson, 1991), 
the opioid system is also highly implicated in the regulation of reward processing (Koob, 
1992) and stress response (Bruchas et al., 2010). The endogenous opioid system is 
composed of three principal families of G-protein coupled receptors (GPCRs), mu 
(MOR), kappa (KOR), and delta (DOR), which interact with the peptides β-endorphin, 
dynorphin, and enkephalin, respectively. Opioid receptors and their peptides are widely 
expressed throughout the peripheral and central nervous system (Mansour et al., 1994; 
Wittert et al., 1996). Within the brain, opioid receptors are primarily distributed in the 
cortex and limbic system (Mansour et al., 1988). Opioid receptors localized to 
mesocorticolimbic DA pathway are thought to mediate both the reinforcing properties of 
rewards and the aversive properties of stressful experiences.   
 Activation of MORs expressed by GABAergic interneurons in the VTA disinhibit 
the activation of DA neurons and facilitate DA release in the NAc (Johnson and North, 
1992; Spanagel et al., 1992b), an essential molecular component of reward processing 
(Contet et al., 2004). Studies in mice with genetic deletion of opioid receptors have 
helped to establish that MORs mediate the reinforcing properties of addictive 
substances, including morphine, nicotine, and ethanol (Matthes et al., 1996; Kieffer and 
Gaveriaux-Ruff, 2002). Importantly, MORs also influence the processing of natural 
rewards, as evidenced by reduced operant responding for both standard chow and 
sucrose pellets in MOR knockout animals compared to wildtype (Papaleo et al., 2007). 
Furthermore, activation of MORs in hedonic “hot-spots” within the NAc shell stimulates 
positive orofacial reactions to food and increases consumption (Pecina and Berridge, 
2005). The role of DORs in reward processing is not as clear, however deletion of DORs 
or its endogenous ligand results in increased levels of anxiety and depressive-like 
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behavior, suggesting that these receptors are more involved in mood-enhancing 
processes (Konig et al., 1996; Filliol et al., 2000; Ragnauth et al., 2001).    
 In contrast, to the MOR and DOR, the KOR is more implicated in mediating the 
aversive properties of stress or stimuli with negative emotional valence (McLaughlin et 
al., 2003; McLaughlin et al., 2006a; McLaughlin et al., 2006b; Lutz and Kieffer, 2013). 
Prolonged exposure to environmental stress can give rise to dysregulation of the 
dynorphin-KOR modulatory system resulting in increased levels of dynorphins in 
mesocorticolimbic regions (Shirayama et al., 2004; McLaughlin et al., 2006b). Activation 
of KORs induce depressive-like and anxiety-like behaviors in rodents (Carlezon et al., 
2006; Van't Veer and Carlezon, 2013) and reduce DA release in key brain regions 
involved in the processing of reward and motivation,(Svingos et al., 1999; Shirayama et 
al., 2004; Flaisher-Grinberg et al., 2012). Notably, stimulation of KORs in the NAc region 
decreases DA transmission, whereas administration of a KOR antagonist increases DA 
transmission (Spanagel et al., 1992a). Moreover, infusion of a KOR agonist into the NAc 
produces robust conditioned place aversion (Bals-Kubik et al., 1993). Facilitation of 
stress-like effects by KOR activation is mediated in part by interactions with the 
neuroendocrine system as evidenced by the finding that the behavioral and 
neurochemical effects of environmental stress or exogenous CRF exposure are blocked 
by treatment with KOR antagonists (McLaughlin et al., 2003; Land et al., 2008).  
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FIGURE 1.2 
 
The endogenous opioid system modulates DA transmission within the mesolimbic 
pathway. KOR, kappa opioid receptor; MOR, mu opioid receptor. Adapted from Carroll 
& Carlezon (2013).  
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Rodent models of stress-induced depression 
	  
There is no singular animal model or paradigm that perfectly recapitulates the complex 
symptomology of depression. However, converging lines of evidence support stress-
induced molecular changes as a key mediator of the onset and progression of 
depressive symptoms in humans. To that end, stress models of depressive behavior in 
animals have utilized realistic and relevant inducing conditions to simulate critical 
physiological components of the psychiatric condition (construct validity). Moreover, 
these models have been shown to demonstrate face validity by producing behavioral 
and physiological changes that parallel the symptom profile of depression.  Finally, 
animal models relevant to depression can be shown to demonstrate predictive validity by 
responding appropriately to antidepressant drugs that are effective in humans).  
Chronic Mild Stress (CMS) 
The theoretical rationale for the CMS paradigm is derived from the clinical observation 
that depressive episodes are often precipitated by an accumulation of life stressors, and 
that stressors perceived as unpredictable or uncontrollable stressors are more 
associated with the onset of depression (Kendler et al., 2003). The procedure, first 
developed by Katz (1981), involved exposing subjects to a variety of severe stressors for 
a period of three weeks. In the late 1980s, Willner and colleagues modified the paradigm 
to avoid the use of severe stressors and instead utilize mild stressors (e.g. change of 
cage mate, overnight illumination, food/water deprivation) presented in a semi-
randomized sequence to model unpredictability and prevent habituation to the stressors 
(Willner et al., 1987). The procedure was originally targeted at modeling anhedonia, due 
to the fact that chronically stressed animals consistently exhibited reduced preference 
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for a sweetened solution, suggesting stress-induced modulation of reward sensitivity. 
Additional studies have gone on to show that CMS exposure also elicits a wide variety of 
behavioral and pathophysiological effects, including anxiogenic and depressive-like 
behaviors, neurochemical changes and alterations in neuroplasticity (Willner, 2005). 
Importantly, many of these effects have been shown to be reversed by antidepressant 
treatment.  
 The many pathophysiological changes resulting from CMS provide a 
comprehensive model of symptomologies that parallel the human condition when 
exposed to stress and serve as an invaluable tool for the evaluation of neurobiological 
mechanisms underlying affective behavior. The disadvantage of this model, however, is 
the long duration and labor-intensive aspects of the procedure. Moreover, many 
researchers have expressed frustration in the reproducibility of CMS-induced effects 
between laboratories. Adoption of a standardized CMS protocol may help to increase 
consistency in findings in the future.  
Chronic CORT Treatment 
The chronic CORT paradigm was developed as an etiologically relevant model of 
depressive disorders characterized by hyper-activation of HPA axis activity. Indeed, 
hypercortisolemia is frequently observed in MDD patients exhibit, which is thought to be 
associated with some of the behavioral and cognitive deficits observed in depression. In 
this paradigm exogenous CORT is delivered directly via oral administration, slow-release 
CORT pellets, or serial injections for a period of 14 or more days. Along with elevating 
circulating levels of CORT, chronic CORT treatment has been shown to reduce sucrose 
preference and operant responding for rewards (Gourley and Taylor, 2009), increase 
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behavioral despair as measured by immobility in the forced swim test and tail-
suspension test (Gourley et al., 2008; David et al., 2009) and increase anxiety-like 
behavior in the light-dark emergence task (Ardayfio and Kim, 2006). In addition, chronic 
CORT treatment consistently reduces hippocampal cell proliferation and survival while 
reducing expression of neurotrophins such as BDNF (Czeh et al., 2001; Bilsland et al., 
2006; Murray et al., 2008). Notably, many of the neurochemical and behavioral changes 
produced by chronic CORT treatment are reversed by antidepressant treatment, thus 
lending to the predictive validity of this model.  
 The advantage of chronic CORT treatment is several-fold. The procedure is 
significantly less complex compared to the CMS protocol, and can easily be replicated 
and confirmed by independent research groups. Whereas the CMS procedure may 
produce varying degrees of CORT response in individual animals, the exogenous 
administration strategy ensures that all animals are exposed to identical levels of CORT. 
Although, it is possible that individual variations in HPA axis reactivity can influence the 
behavioral and physiological consequences of exogenous CORT exposure. A limitation 
of this method is that the HPA axis is only one of many systems that respond to stress. 
Thus, the pathophysiological effects of CORT treatment alone are not necessarily 
reflective of total exposure to physiological stress. There is also some variation between 
laboratories in the way that CORT exposure is accomplished. Nonetheless, exogenous 
administration of CORT enables investigation into how CORT specifically contributes to 
the development of stress-induced changes in behavior and physiology	  
Behavioral tests of anhedonia 
 
Sucrose Preference Test 
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The sucrose preference test is a measure of hedonic sensitivity to rewarding stimuli. In 
this procedure, animals are given the choice of consuming either water or a 
saccharin/sucrose solution. Non-stressed mice exhibit increased consumption of the 
sweetened solution, whereas animals exposed to stress exhibit substantial reductions in 
preference for the sweetened solution. This finding has long been hypothesized to model 
reduced perception of rewards, and is thus often cited as an animal measure of 
anhedonia. A hallmark of the CMS procedure is the demonstration of reduced sucrose 
preference among stressed animals (Willner, 2005). Chronic treatment of stressed 
animals with antidepressants restores sucrose preference, reflecting the way that 
antidepressants have been shown to work in humans. Reduction in sucrose preference 
after CMS is a controversial endpoint, however.  Since stressed animals also experience 
significant weight loss compared to non-stressed animals, sucrose intake data may be 
adjusted to include weight differences between the two groups.  In some instances, 
differences in sucrose preference sometimes become insignificant when this is done 
(Matthews et al., 1995; Forbes et al., 1996). However, other laboratories have shown 
this finding to hold true irrespective of changes in body weight (Willner, 1997).  Another 
limitation of this test is that it doesn’t take into consideration the motivational aspects of 
anhedonia, which appears to be the principal deficit in human populations. In fact, when 
asked to rate the pleasantness of different concentrations of sucrose solutions, there is 
no difference in hedonic value between depressed individuals and healthy controls 
(Amsterdam et al., 1987; Berlin et al., 1998; Dichter et al., 2010). Regardless, the 
sucrose preference test continues to be a widely used behavioral measure of anhedonia 
in animals. 
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Conditioning Paradigms 
Approach motivation, the mobilization of energy by or toward a positively valenced 
stimulus, is a fundamental component of reward-seeking behavior (Lewin, 1935). 
Pavlovian conditioning theory posits that temporal pairing of a neutral conditioned 
stimulus, such as an environmental cue, with an appetitive unconditioned stimulus, such 
as food, can result in the acquisition of an approach response to the conditioned 
stimulus in subsequent events. Appetitive reactions evoked by the conditioned stimulus 
signal attribution of incentive salience, or “wanting”, thus maintaining learned behaviors 
that facilitate acquisition of the rewarding or desired outcome. Alterations in conditioned 
approach behavior may signal dysregulation of the neural mechanisms that translate 
incentive learning into motivated behavioral output.  
Operant Responding 
Operant responding, also known as instrumental learning, is an oft-used measure of 
motivational drive for rewarding stimuli in rodents. Rodents are trained to associate an 
instrumental response (e.g. lever pressing) with a conditioned stimulus. Presentation of 
the conditioned stimulus leads to an increase in instrumental responding. This paradigm 
can be further adapted to utilize a progressive ration (PR) procedure in which the 
experimenter progressively increases the number of lever presses required to obtain 
each subsequent award (Hodos, 1961). The final ratio achieved by the animal before 
discontinuing lever presses is referred to as the “break point” and is reflective of the 
subject’s motivation or willingness to work for a reward. Operant paradigms provide a 
more sensitive measure of motivational output compared to consummatory measures, 
such as the sucrose preference test. It is important to note, however, that under a PR 
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schedule animals periodically receive the reward as they successfully progress to the 
next fixed ratio. The intermittent reinforcement of reward may contribute to sustained 
levels of operant behavior, thus potentially obscuring the effects of experimental 
manipulations on motivational drive in this paradigm.    
 Intracranial self-stimulation (ICSS) is an operant conditioning based behavioral 
paradigm in which animals learn to self-deliver brief electrical pulses into specific brain 
regions implicated in brain reward circuitry, most notably the lateral hypothalamus (LH) 
(Olds and Olds, 1963) and VTA (Miliaressis et al., 1975). Dopaminergic fibers from the 
VTA to the NAc pass through the LH and are innervated by peptidergic projections from 
the LH that are thought to mediate rewarding responses to drugs of abuse (Fulton et al., 
2000; Kelley and Berridge, 2002; Kiefer and Wiedemann, 2004; Harris et al., 2005). 
Acute administration of drugs of abuse lower ICSS thresholds (Vlachou and Markou, 
2011), whereas CMS exposure increases ICSS thresholds, suggesting reduced 
sensitivity to rewards reflective of an anhedonic state (Moreau et al., 1995). Similar to 
traditional operant responding paradigms, ICSS allows for quantitative assessment of 
behavioral output for rewarding stimuli. However, ICSS directly activates reward-
processing systems while bypassing sensory modulatory inputs (e.g. palatability) that 
may be involved in motivational salience.  
Conditioned Place Preference (CPP) 
The conditioned place preference paradigm utilizes Pavlovian conditioning to assess the 
rewarding or aversive effects of a particular treatment or event (Tzschentke, 2007). In 
this procedure, a drug or non-drug treatment is repeatedly paired with distinctive 
environmental cues. Eventually the animal learns to associate the contextual cues with 
the rewarding (or aversive) properties of the treatment and will choose to spend more (or 
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less) time in the conditioned environment even in the absence of the original stimulus. 
The CPP test is a powerful tool for investigating the neurobiological mechanisms 
underlying the reinforcing properties of salient stimuli. However, because animals 
passively receive the treatment, this paradigm may not fully address the effort-based 
mechanisms associated with motivated behavioral output.  
Novelty-induced hypophagia (NIH) test 
The unconditioned suppression of feeding in a novel environment, commonly referred to 
as hyponeophagia, is a well-documented phenomenon in rodents. Thus the novelty-
induced hypophagia (NIH) test taps into stress-induced changes in conditioned 
approach behavior. In this paradigm animals are trained over a period of days to rapidly 
approach and consume a highly palatable food reward in their home cage environment. 
Once stable approach latencies for the food are established, animals are examined for 
their appetitive and consummatory behavior in a brightly lit and differently scented novel 
arena. Untreated animals consistently exhibit a robust increase in latency to approach 
the food and reduced food consumed in the novel arena compared to the home cage. 
Chronic treatment with antidepressant drugs reverses this effect. Interestingly, acute 
treatment with an anxiolytic drug also reduced approach latency in this paradigm 
(without altering home cage behavior), which led researchers to conclude that this 
paradigm is a measure of anxiety-like behavior in rodents (Bodnoff et al., 1988; Bodnoff 
et al., 1989; Dulawa and Hen, 2005). Alternatively, approach latency in the novel arena 
may reflect altered motivational drive for rewarding stimuli. The distinct suppression of 
approach behavior in the novel arena enables investigation into how aversive cues 
contribute to diminished incentive salience for natural rewards.   
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Goals of research 
	  
The overarching goals of this thesis research were to further elucidate the mechanisms 
underlying stress-induced changes in motivational drive and in the process identify 
potential pharmacological targets for the prevention or reversal of affective behavior. The 
majority of studies examining the neurobiological underpinnings of motivated behavior 
for natural rewards has been conducted in rats and has at times conflated hedonic 
processes and motivational output in their assessment of anhedonic behavior. In this 
thesis work we employed a single conditioned approach behavioral paradigm in mice in 
which “liking” (amount of food consumed) and “wanting” (latency to approach the food) 
behaviors could de easily dissociated so as to simultaneously measure the motivational 
aspects and neurochemical substrates underlying incentive salience for a salient 
stimulus. Once characterizing the core neurochemical phenotype associated with stable 
approach behavior, we uncovered the effects of stress on these same neural processes, 
thus establishing a unique role for NAc DA in the onset and maintenance of incentive 
behavior in mice. Next, using the same behavioral paradigm we identified distinct 
pharmacological targets within the brain opioid system as potential mediators of 
conditioned approach behavior under stress.  Lastly, we sought to address the role of 
stress hormones in mediating behavioral response to the selective serotonin reuptake 
inhibitor (SSRI) fluoxetine in the NIH paradigm. Together, these findings help to broaden 
our understanding of the mechanisms underlying anhedonic behavior in stress related 
psychiatric disorders.  
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Abstract  
 
Anhedonia is a hallmark symptom of several psychiatric disorders, including depression, 
schizophrenia and post-traumatic stress disorder. Given the frequent presentation of 
anhedonia in stress-related psychiatric disorders, we assessed the effects of stress on 
the motivational and neurochemical correlates underlying conditioned approach behavior 
for palatable food in the mouse.  The effect of palatable food exposure was measured on 
dopamine release in the nucleus accumbens (NAc), a region known to play a prominent 
role in food reward behavior in awake freely moving C57BL/6J mice using in vivo 
microdialysis.  Animals trained to consume food in a familiar environment exhibited a 
significant 30% elevation in NAc dopamine release coincident with the presentation of 
food. This effect was not seen in animals that consumed the food in an unfamiliar 
environment or interacted with the food reward for the first time and was region specific. 
Presentation of an acute stressor (bright light and novel scent) during food exposure 
blocked dopamine release and delayed approach behavior in response to the food 
reward in trained animals. These effects were reversed in animals pretreated with 
buprenorphine, a mixed opioid drug shown previously to produce antidepressant-like 
and anxiolytic effects.  Together, these data indicate that exposure to mild stress 
reduces incentive drive to approach palatable food via alterations in NAc dopamine 
responsiveness to the food reward. Moreover, they implicate the brain opioid system as 
a potential pharmacological target for treatment of anhedonia  
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Introduction  
 
Anhedonia, the lost of interest or pleasure in typically enjoyable or rewarding activities, is 
a hallmark symptom of several psychiatric disorders including depression, schizophrenia 
and post-traumatic stress disorder. Although trait anhedonia encompasses both 
consummatory and motivational components, clinical studies indicate that the major 
deficit lies in motivational output as opposed to processing of hedonic value (Burbridge 
and Barch, 2007; Sherdell et al., 2012; Argyropoulos and Nutt, 2013). Dopamine (DA) 
neurotransmission has long been known to be involved in the processing of reward and 
motivation, and more recently shown to modulate depressive-like behavior in rodents 
(Chaudhury et al., 2013; Tye et al., 2013). Yet, the manner in which altered DA activity 
influences changes in behavior is still not well understood.  
 The brain’s reward system is composed in part of mesolimbic DA neurons 
originating in the ventral tegmental area (VTA) that project to and innervate several 
limbic structures including the nucleus accumbens (NAc).  Dopaminergic innervation of 
the NAc is thought to play a critical role in mediating the reinforcing properties of both 
drugs of abuse and natural rewards.  Studies conducted largely in rats have measured 
phasic increases in extracellular concentrations of DA in the NAc in response to both 
initial consumption of a palatable food reward and the instrumental responding for food 
(Bassareo and Di Chiara, 1997; Ahn and Phillips, 2007). On the other hand, depletion or 
inhibition of DA activity in the NAc reduces goal-directed behavior towards food, but 
does not diminish hedonic reactions to food (Berridge, 2007, 2012a). Thus, 
dopaminergic signaling in the NAc is likely involved in both initiating unconditioned 
appetitive behavioral responses and eliciting cue-triggered incentive salience (Berridge 
and Robinson, 1998; Cardinal et al., 2002; Parkinson et al., 2002; Cone et al., 2016). 
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However, very little work has been done in evaluating the relationship between NAc DA 
reactivity to food stimuli and approach behavior in other species, such as mice, which 
exhibit different approach and appetitive behaviors to novel and familiar foods.  
 Given the frequent presentation of anhedonia in stress-related psychiatric 
disorders, exposure to stress may contribute to the dysregulation of reward circuitry. The 
endogenous opioid system has been implicated in mediating the aversive properties of 
stress (McLaughlin et al., 2003; McLaughlin et al., 2006b; Lutz and Kieffer, 2013b) and 
has been shown to either facilitate or reduce DA release in key brain regions involved in 
processing of reward and motivation, including the NAc (Svingos et al., 1999; Shirayama 
et al., 2004; Bruchas et al., 2009; Flaisher-Grinberg et al., 2012a). Recent studies in 
animals have revealed promising effects of opioid drugs, such as buprenorphine (BPN), 
in ameliorating anxiety and depressive like behaviors induced by stress (Almatroudi et 
al., 2015; Browne et al., 2015; Falcon et al., 2015; Falcon et al., 2016b). Moreover, 
clinical trials have shown BPN to have therapeutic effects in treatment-resistant human 
populations (Bodkin et al., 1995a; Nyhuis et al., 2008; Ehrich et al., 2014).  
 The goal of the present study was to use a single behavioral paradigm in mice to 
simultaneously measure the motivational aspects and neurochemical substrates 
underlying approach behavior for palatable food reward. Changes in extracellular DA 
levels in the NAc and behavior were measured during the presentation of palatable food 
to non-deprived C57BL/6 mice using in vivo microdialysis. Comparison of the effects of 
conditioned versus unconditioned food stimuli on NAc DA release and approach 
behavior established that prior exposure to food reward was necessary to produce food-
cued DA reactivity in the NAc and that this response reflected both anticipatory and 
consummatory signals. DA levels in the striatum were unaffected. Once the core 
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neurochemical phenotype associated with stable approach behavior was established, 
we demonstrated that exposure to an acute stressor during food presentation inhibited 
the NAc DA response to a conditioned food stimulus and reduced motivational salience 
for the reward, as measured by increased latency to approach.  Lastly, we showed that 
pretreatment with the mixed-opioid drug BPN prevented both the neurochemical and 
behavioral effects of stress in this paradigm.  
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Materials and Methods 
	  
Animals 
Male C57BL/6 J mice, 7-8 weeks old upon arrival, were purchased from Jackson 
Laboratories (Bar Harbor, ME). Mice were housed in pairs in polycarbonate cages and 
maintained under a 12 hour light-dark cycle (lights on at 0700 hours) in a temperature 
(22 °C)- and humidity-controlled environment. Chow and water were available ad libitum. 
All experiments were approved by the Institutional Animal Care and Use Committee at 
the University of Pennsylvania.  
Drugs 
Buprenorphine hydrochloride (Sigma, St. Louis, MO) was dissolved in distilled water and 
injected intraperitoneally (i.p.). The dose was calculated according to the base weight of 
the drug and administered in a volume of 10 ml/kg. 
Surgery 
Microdialysis probes were custom-made and surgically implanted in mice as described 
previously (Knobelman et al., 2001). Under isoflurane anesthesia, the probe was 
implanted in the nucleus accumbens [ +1.2 mm anteroposterior (AP), ±0.5 mm 
mediolateral (ML) from bregma, −4.5 mm dorsoventral (DV) from dura]  or dorsal 
striatum (+1.0 mm AP, ±1.7 mm ML fro bregma, −4.5 mm DV from dura) (Franklin and 
Paxinos, 1997) using a stereotaxic instrument.  BPN treated mice were injected with 
drug immediately after completion of surgery while still anesthetized. Untreated animals 
received no injection. Following surgery, the mice were placed into a 21.5 cm high, clear 
polycarbonate cylindrical in vivo microdialysis chamber with a counterbalance arm 
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holding a liquid swivel (Instech Laboratories, Plymouth Meeting, PA) and allowed to 
recover overnight with the pump flow rate set to 0.9 µl/min. For testing the flow rate was 
set to 2.2 µl/min.  Dialysate samples were collected into polypropylene microcentrifuge 
vials and stored at −80 °C until analyzed for dopamine as described previously (Andrews 
and Lucki, 2001) using a Shimadzu Prominence HPLC system (including a LC-20 AD 
pump and Sil-20 AC refrigerated microsampler) using a Unijet microbore column (3 µM 
ODS/ 100 × 1 mm) coupled with an Antec Decade II electrochemical detector. DA levels 
were identified by comparing their elution times with those of reference standards and 
quantified from their respective peak heights using a linear regression analysis of the 
peak heights obtained from a series of reference standards.  
Experimental procedures 
Mice were trained to consume three (~1.4g) Reese’s peanut butter chips (The Hershey 
Company, Hershey, PA) presented in a small, clear petri dish in a home cage 
environment in daily 15-minute sessions. Opaque, black, plastic dividers were placed 
inside each home cage to separate the mice during training sessions. Mice were allowed 
to habituate to the dividers for 1 hour before the start of the training session. Sessions 
continued until animals approached the food reward in less than 30 seconds for three 
consecutive days. Mice assigned to the “test cage” trained group received five additional 
training sessions in the microdialysis chamber.  Mice assigned to the “home cage” 
trained group underwent surgery after meeting criteria in the home cage and were tested 
in the microdialysis procedure without prior food exposure in the microdialysis chamber. 
Mice assigned to the “no training” group were naïve to the food reward and received no 
training prior to surgery and testing. All animals were tested in the microdialysis 
chamber.  
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Microdialysis experiments started 17–20 hours after surgery. The pump flow rate 
was increased to 2.2 µl/min two hours prior to testing. Baseline dialysate samples were 
collected at five-minute intervals starting one hour prior to food exposure. The final three 
samples were used to establish a baseline value before food exposure. During food 
exposure, a small clear petri dish with three peanut butter chips was placed in the 
microdialysis chamber for fifteen minutes and 3 samples were collected. Three 
additional samples were collected after the food dish had been removed. At the 
completion of the experiment, the mice were sacrificed and their brains were removed, 
placed in cold isopentane, and frozen at −80 °C. The brains were then sectioned (35 
µm) with a refrigerated cryostat and the tissue examined for the location of the dialysis 
probe. 
Behavioral recordings 
Mice were evaluated for their responses to food presentation in the microdialysis 
chamber. The latency to eat the peanut butter chips and the amount consumed during 
the 15-minute feeding period was live recorded for each animal. Mice were also 
monitored for defensive burying (aggressive shoveling movement of bedding material 
with forepaws), rearing (standing on hindpaws), grooming (nose/face/body washing), 
and idle (absence of active moments) behavior before, during, and after food 
presentation. For each behavioral category, mice received a score of either “1” if they 
engaged in the behavior within the 5 minute sampling time or “0” if they did not. The 
scores were averaged among animals in each group for each time point, thereby 
reflecting the proportion of animals engaging in a particular behavior at a given time.   
 
	  52	  
	  
Data analysis 
One-way and two-way ANOVA were performed to examine the significance of 
differences between experimental groups. Significant overall main effects were followed 
by Dunnett’s or Holm-Sidak’s multiple comparisons test where appropriate. Microdialysis 
data were expressed as a percentage of baseline values determined by the mean of 
three samples collected immediately before food presentation. A repeated measures 
two-way ANOVA was used to compare variations in DA levels within experimental 
groups and significant differences were followed by Dunnett’s test. Variations in DA 
levels between groups were compared at individual time points using Tukey’s test. For 
all tests, p<0.05 was considered statistically significant. Data are expressed as mean 
±SEM. 
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Results 
	  
The effects of training experience on DA response and approach behavior to palatable 
food 
To determine whether familiarity with the food reward and feeding environment impacts 
DA response and approach behavior to palatable food in C57BL/6J mice, we first 
evaluated the effects of training experience on NAc DA reactivity and latency to 
approach and consume the food. Repeated-measures two-way ANOVA revealed a 
significant effect of training experience [F(2, 15)=9.884, p=0.002] and an interaction 
between training experience and time [F(16, 120) = 2.713, p=0.001] on extracellular DA 
levels in response to the food presentation. Multiple comparisons indicated that food 
presentation significantly increased extracellular DA levels (~30%) in the NAc of animals 
exposed to food in the test cage (p<0.05). DA levels remained high after the food was 
removed. This response was attenuated in animals allowed to consume the food in 
feeding cages but not in the test cage (home cage trained animals) and returned to 
baseline levels after removal of the food.  Animals that were naïve to the peanut butter 
chips did not demonstrate significant variation of DA levels during or after presentation of 
the food (Figure 2.1A). 
 Differing approach latencies between groups [F(2,15]=84.98, p <0.001] paralleled 
the association between DA levels and food presentation (Figure 2.1B). Animals 
interacting with the food reward for the first time had a significantly higher approach 
latency compared to test cage and home trained animals (p <0.001). Similarly, the 
amount of food consumed differed between groups [F(2,15)=14.92, p=0.003]. As 
illustrated in Figure 2.1C, test cage trained and home cage trained animals consumed 
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more of the peanut butter chips compared to untrained animals (p < 0.01).  
 Determination of a behavioral profile, by measuring burying, rearing, grooming, 
and idle behavior before, during, and after food presentation, provided additional 
information on the differential effects of training experience. Animals with no previous 
experience with the food reward showed significantly more burying behavior during food 
presentation compared to test cage and home cage trained animals. A two-way ANOVA 
revealed a significant main effect of time [F(8,120)=8.658, p<0.0001] and an interaction 
between training experience and time [F(16, 120)=2.401, p=0.016] on the amount of 
burying behavior (Figure 2.2A). A significant main effect of time was also observed for 
rearing [F(8, 120)=4.074, p<0.003] (Figure 2.2B) and grooming [F(8,120)=2.562, 
p<0.013] (Figure 2.2C) behaviors. Animals from all groups exhibited more rearing and 
grooming behavior following food presentation. Analysis of the time spent idle showed a 
significant main effect of time F(8,120)=12.05, p<0.0001] and an interaction between 
groups F(16,120)=3.072, p<0.0002]. Home cage trained and animals without training 
spent more time idle prior to food exposure compared to test cage trained animals 
(Figure 2.2D). Moreover, untrained animals spent more time idle during food 
presentation compared to test cage and home cage trained animals.  
NAc DA is responsive to anticipatory and consummatory cues for palatable food 
Having demonstrated that mice trained to feed in the test cage exhibit DA reactivity to 
food exposure, we next sought to address whether the NAc DA response is an appetitive 
signal or dependent on consummation of the food reward. To test this, we presented test 
cage trained animals with empty petri dishes (in which the peanut butter chips were 
previously stored) while sampling from the NAc (Figure 2.3A). In the absence of food, we 
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observed a 40% elevation in DA in response to presentation of the food dish 
F(8,32)=5.184, p=0.003].  
NAc DA response to palatable food is not reflective of generalized striatal activity 
To examine the regional specificity of the food-induced DA response, a separate cohort 
of test cage trained animals was implanted with microdialysis probes in the dorsal 
striatum. As seen in Figure 2.3B, food presentation had no effect on extracellular DA 
release in this region F(8,24)= 1.663, p=0.160], although these animals exhibited similar 
approach latencies and food consumption to animals who received probe implants in the 
NAc (data not shown).  
BPN prevents effects of stress on NAc DA response and approach behavior 
The next experiment measured how stress exposure influences the NAc DA response to 
a familiar food reward and approach behavior. Repeated measures ANOVA revealed a 
significant effect of treatment [F(2,19)=9.848, p=0.001], time [F(8,152)=3.454, p=0.001], 
and an interaction [F(16, 152)=2.541, p=0.002]. Animals exposed to acute stress, a 
bright light and novel scent during food presentation, exhibited no change in extracellular 
DA in response to the food reward (Figure 2.4A). In contrast, animals treated with BPN 
24 hours prior to testing showed restored DA response to the palatable food reward.  
 Exposure to stress also increased latency to approach the food compared to 
unstressed animals (Figure 4B). A one way ANOVA also revealed a significant effect of 
stress on latency to approach the food reward [F(2,19)=4.735, p=0.021]. This effect was 
reversed in animals pretreated with BPN. Interestingly, there was no significant 
difference between groups in amount of food consumed [F(2,19)=0.040, p=0.961] 
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(Figure 2.4C).  
 Examination of the behavioral profile indicated differences in burying and rearing 
behaviors before, during, and after food presentation between groups. There was a 
significant main effect of time on burying behavior [F(8,152)=6.068, p=0.001] (Figure 
2.5A). For rearing behavior, there was a significant main effect of time [F(8,152)=6.958, 
p=0.001] and an interaction [F(16, 152)=2.242, p=0.006]. Untreated animals exposed to 
the stressor exhibited increased rearing during and after the feeding period compared to 
unstressed animals (Figure 2.5B). There were also significant main effects of time on 
grooming [F(8,152)=2.816, p=0.006] and idle [F(8,152)=6.848, p=0.001] behavior. 
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Discussion 
  
The present study is the first to establish in mice that repeated exposure to palatable 
food elicits DA efflux in the NAc, and that the major component of the DA response is 
associated with the conditioned incentive salient effects, as measured by the decreased 
latency to approach the food. Because mice were not food deprived prior to testing, 
approach behavior likely represents motivational “wanting” as opposed to a homeostatic 
drive to feed. Presentation of the palatable food in an unfamiliar feeding environment, or 
to mice that were naïve to the food reward, failed to elicit a NAc DA response. The DA 
response was limited to the NAc and did not occur in the striatum. Altogether, these 
findings indicate a critical role for NAc DA transmission as a substrate for facilitating the 
emergence and maintenance of motivated behavioral output for food reward. 
Furthermore, we showed that exposure to stressful stimuli during food presentation 
diminishes the NAc DA response and increases approach latency to the conditioned 
food stimulus. Remarkably, pretreatment with BPN 24 hours prior to testing blocked the 
effects of stress on NAc DA reactivity and restored approach behavior for the food, 
suggesting a role for opioid systems in mitigating the aversive effects of stress on 
incentive salience for natural rewards.  
 There is an expansive body of literature implicating a role for DA in mediating 
reward-seeking behavior for natural reinforcers, the majority of which have been 
conducted in rats (Ikemoto and Panksepp, 1999). Although the present study design is 
similar in some respects to those done in rats, our findings reveal key disparities in the 
correlational relationship between NAc DA response to food and incentive behavior. 
Notably, in rats, consumption of a novel food, but not a familiar food, stimulates DA 
release in the NAc (Bassareo and Di Chiara, 1997; Gambarana et al., 2003). Thus, DA 
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response to a novel food in rats likely serves as a learning cue that is subject to 
habituation following repeated exposure. In contrast, we show that repeated exposure to 
a food stimulus in a familiar feeding environment is necessary to induce a DA response 
in the mouse NAc. Furthermore naïve mice exhibited more burying and idleness during 
food presentation, suggesting that the animals found the novel food aversive rather than 
appealing. Overall, these findings highlight the importance of environmental context in 
the emergence of conditioned neurochemical and behavioral responses to rewards in 
the mouse.  
 In rats, stimuli that predict a reward consistently promote DA release in the NAc, 
whereas the DA response to physical consumption of the reward is variable (Cenci et al., 
1992; Salamone et al., 1994; Martel and Fantino, 1996; Hajnal and Norgren, 2001). In 
the current study, test cage trained mice presented with the predictive stimulus (empty 
food dish) exhibited a sharp rise in NAc DA efflux that rapidly returned to baseline. 
However, in animals allowed to feed DA efflux persisted throughout food presentation 
and after removal of the food. Therefore, NAc DA transmission in mice is responsive to 
both anticipatory and consummatory cues.   
 The chronic mild stress (CMS) paradigm has repeatedly been shown to reduce 
preference for a sucrose solution in rodents. (Papp et al., 1991; Willner et al., 1992; 
Rygula et al., 2005; Willner, 2005). Optogenetic activation of VTA DA neurons restores 
sucrose preference in mice after CMS exposure, implicating a role for the mesolimbic 
DA system in mediating stress-induced changes in reward processing (Tye et al., 2013). 
Although reduced sucrose preference is often cited as an anhedonic effect, the 
translational value of this test is limited in that it more closely models changes in hedonic 
value of a reward, which is not typically observed in anhedonic patients (Berlin et al., 
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1998; Dichter et al., 2010). CMS has also been shown to blunt NAc DA reactivity to 
palatable food in rats (Di Chiara and Tanda, 1997; Di Chiara et al., 1999; Gambarana et 
al., 2003). However, because stress did not alter approach behavior or food 
consumption in these studies, it is difficult to interpret how diminished NAc DA response 
influenced motivational salience. 
 In the present study we adapted a hyponeophagia-based paradigm to model how 
stress affects the neurochemical underpinnings of motivational drive. The suppression of 
feeding in a novel environment is a well-documented phenomenon in rodents and often 
used to assess emotionality and anxiety.  Chronic treatment with antidepressants or 
acute treatment with anxiolytic drugs reduces approach latencies for food in a novel 
environment, suggesting a restoration of incentive salience for the food (Bodnoff et al., 
1988; Bodnoff et al., 1989; Dulawa and Hen, 2005). We hypothesized that reduction in 
NAc DA transmission in response to food presentation by a stressful or unfamiliar 
environment may be associated with changes in approach behavior, and possibly serve 
as a neurochemical substrate of a component of anhedonia. Indeed, presentation of a 
bright light and novel scent during food exposure blunted NAc DA reactivity to the 
conditioned food stimulus and significantly increased the time to consume the food. 
Interestingly, the amount of food consumed was not altered in animals exposed to the 
novel stimuli, signifying that stress specifically alters neurocircuitry associated with 
motivational drive as opposed to hedonic value. These findings are in line with the 
incentive salience theory which postulates that hedonic “liking” and motivational 
“wanting” are independent psychological processes controlled by different neural 
mechanisms (Berridge, 2007; Wise, 2008a). Specifically, the theory posits a role for DA 
in mediating appetitive goal-directed behavior. Hence, anhedonic behavior may derive 
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from alterations in dopaminergic activity that would normally promote motivational 
salience. 
 The brain opioid system has long been known to play a role in mediating reward 
seeing-behavior.  Activation of mu-opioid receptors (MORs) in the ventral tegmental area 
results in increased DA release in the NAc, an effect that is associated with increased 
intake of palatable food (Spanagel et al., 1992; Zhang et al., 2003; Pecina and Berridge, 
2005; Katsuura and Taha, 2010; Murray et al., 2014). In contrast, activation of kappa 
opioid receptors (KORs) in the NAc inhibits DA neurotransmission and induces 
prodepressive behaviors in rodents (Maisonneuve et al., 1994; McLaughlin et al., 
2006b). Moreover, exposure to stress increases levels of dynorphins (the endogenous 
ligand of KORs) in limbic regions. Consequently, increased activation of KOR is a 
potential mechanism in which stress diminishes DA reactivity to food reward. It is 
important to note, however, that physical stressors can also increase DA efflux in the 
NAc (Thierry et al., 1976; Abercrombie et al., 1989; Imperato et al., 1992; Kalivas and 
Duffy, 1995a). Thus, environmental stress may differentially affect NAc DA 
neurotransmission in response to expected rewards.  
 BPN is a mixed-pharmacology opiate drug, with potent activity as a partial 
agonist at the mu-opioid receptor (MOR) and antagonist at kappa-opioid receptors 
(KOR) (Lutfy and Cowan, 2004; Cowan, 2007). Our laboratory and others have shown 
that low doses of BPN treatment reduce latency to approach palatable food in a novel 
environment (Almatroudi et al., 2015; Falcon et al., 2015). In the present study BPN was 
effective in restoring approach behavior and NAc DA reactivity to food in animals 
exposed to an acute stressor. Animals were tested 24 hours after BPN administration, a 
time at which the drug is no longer activating MOR, but may still have antagonist activity 
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at KOR (Paronis and Bergman, 2011). Moreover, the dose of BPN used in the current 
study does not alter extracellular DA levels in the NAc when injected 1 hour prior to 
sampling (Falcon et al., 2015); therefore, it is unlikely that DA levels would be altered 24 
hours later. Thus, BPN’s effect in this paradigm may be mediated by inhibition of KOR-
induced reduction in NAc DA, though additional studies are needed to confirm this. 
 DA neurotransmission in the NAc is only one facet of the complex and 
interconnected circuitries that govern the brain reward system. Dopaminergic VTA 
neurons also innervate the medial prefrontal cortex (mPFC) and basolateral amygdala 
(BLA), structures known to mediate the processing of both rewarding and aversive 
stimuli. The mPFC and BLA also send dense glutamatergic inputs to NAc DA terminals, 
which can synaptically facilitate or depress DA efflux in the NAc (Floresco et al., 1998; 
Jackson and Moghaddam, 2001). Moreover, DA transmission in the NAc has been 
shown to interact with corticolimbic glutamate signaling to facilitate the emergence of 
incentive salience for a food reward (Faure et al., 2008). Additional studies are needed 
to determine how stress-induced changes in glutamate transmission modulate DA-
mediated incentive salience. 
 In conclusion, our findings with a mouse model measuring the motivational 
aspects and neurochemical substrates underlying approach behavior for palatable food 
reward suggest a unique role of NAc DA transmission in establishing and mediating 
incentive salience for a palatable food reward in mice. Moreover, we show that exposure 
to an acute stressor is sufficient to alter NAc DA responsiveness to a food reward, which 
in turn diminishes approach behavior. The ability of BPN to prevent changes in 
neurotransmission and behavior caused by stress exposure supports the opioid system 
as a potential target for the development of novel therapeutic treatments of anhedonia 
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and emotional dysfunction.  
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FIGURE 2.1 
 
 
 
Effects of training experience on NAc DA response and approach behavior to 
palatable food. A) NAc DA response to food presentation in test cage trained (n=7), 
home cage trained (n=6), and naïve animals (n=5).  Black bar denotes duration of food 
exposure. Test cage trained animals were the only group to exhibit a significant change 
from baseline in DA levels in response to the food reward. The asterisk denotes 
significant differences compared to baseline values within the test cage trained group 
(*p<0.05, ***p<0.001). The symbol # denotes significant differences in DA release 
between test cage trained and home cage trained animals (#p<0.05). The symbol & 
denotes significant differences in DA release between test cage trained and naïve 
animals (&p<0.05).  B) Naïve animals took longer to approach the food and C) 
consumed less food compared to test cage trained animals. The asterisk denotes a 
significant difference compared to test cage trained animals (***p<0.001, ****p<0.0001). 
Data is depicted as mean ± SEM. 
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FIGURE 2.2 
 
Effects of training experience on behavioral profile. Time course of behavioral 
profiles of test cage trained (n=7), home cage trained (n=6), and naïve animals (n=5). 
Behavior was scored in blocks of 5 minutes and measured before, during, and after food 
exposure. Animals were evaluated for changes in A) burying, B) rearing, C) grooming 
and D) idle behavior. Naïve animals exhibited more burying behavior and idle behavior 
during food presentation. The asterisk denotes a significant difference compared to test 
cage trained animals. (*p<0.05). Data is depicted as mean ± SEM. 
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FIGURE 2.3 
 
DA response to conditioned cues for food reward and effects of food exposure on 
general striatal activity. Black bar denotes duration of conditioned cue or food 
exposure. A) NAc DA response to presentation of a conditioned cue (empty food plate) 
in in test cage trained animals exposed to an empty food plate (n=5). Exposure to the 
empty plate significantly increased NAc DA levels from baseline. The asterisk denotes 
significant differences compared to baseline values (**p<0.01). B) Dorsal striatum DA 
response to food presentation in test cage trained animals (n=4). Food presentation did 
not alter DA transmission in the dorsal striatum. Data is depicted as mean ± SEM.  
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FIGURE 2.4 
 
Effects of stress exposure and BPN treatment on NAc DA response and approach 
behavior to palatable food. A) NAc DA response to food presentation in test cage 
trained animals exposed to a stressor (bright light and novel vanilla scent) during food 
presentation (n=8), and test cage trained animals treated with BPN and exposed to a 
stressor during food presentation (n=7).  Black bar denotes duration of food and stress 
exposure. BPN treatment prevented stress-induced inhibition of NAc DA response to 
food. The asterisk denotes significant differences compared to baseline values within the 
BPN treated group (*p<0.05). The symbol # denotes significant differences in DA release 
between test cage trained animals and untreated test cage trained animals exposed to 
the stressor (##p<0.01, ###p<0.001, ####p<0.0001, analysis includes data from Figure 
2.1A).  The symbol & denotes significant differences in DA release between untreated 
and BPN treated test cage trained animals exposed to the stressor (&p<0.05, 
&&p<0.01). B) Untreated test cage trained animals exposed to the stressor took longer 
to approach the food compared to non-stressed test cage trained animals. Approach 
latency was restored to control values in BPN treated animals. The asterisk denotes a 
significant difference compared to test cage trained animals (*p<0.05, analysis includes 
data from Figure 2.1B).  The symbol # denotes a significant difference between 
untreated and BPN treated test cage trained animals exposed to the stressor (#p<0.05). 
C) There was no significant effect of group condition on amount of food consumed. Data 
is depicted as mean ± SEM.  
	  67	  
	  
FIGURE 2.5 
 
Effects of stress exposure and BPN pretreatment on behavioral profile. Time 
course of behavioral profiles of test cage trained animals exposed to a stressor during 
food presentation (n=8), and test cage trained animals treated with BPN and exposed to 
a stressor during food presentation (n=7). Behavior was scored in blocks of 5 minutes 
and measured before, during, and after food exposure. Animals were evaluated for 
changes in A) burying, B) rearing, C) grooming and D) idle behavior. Untreated animals 
exposed to stress displayed more rearing behavior during food presentation compared 
to non-stressed test cage trained animals. The asterisk denotes a significant difference 
compared to test cage trained animals (*p<0.05, analysis includes data from Figure 2.2). 
Data is depicted as mean ± SEM.  
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Abstract 
 
Buprenorphine (BPN), a mixed opioid drug with high affinity for mu (MOR) and kappa 
(KOR) opioid receptors, has been shown to produce behavioral responses in rodents 
that are similar to those of antidepressant and anxiolytic drugs. Recent studies have 
identified KORs as the primary mediator of BPN’s effects in rodent models of 
depressive-like behavior. However, the role of MORs in BPN’s behavioral effects has not 
been as well explored. The current studies investigated the role of MORs in mediating 
conditioned approach behavior in the novelty-induced hypophagia (NIH) test, a 
behavioral measure previously shown to be sensitive to BPN treatment. The effects of 
BPN were evaluated in the NIH test 24 hr post-administration in mice with genetic 
deletion of MOR (Oprm1-/-) or KORs (Oprk1-/-), or after pharmacological blockade with 
the non-selective opioid receptor antagonist naltrexone.  Behavioral responses to BPN in 
the NIH test were blocked in Oprm1-/- mice, but not Oprk1-/- mice. To further elucidate 
the opioidergic mechanisms underlying behavioral response in the NIH paradigm, 
animals were treated with the MOR agonist morphine, the KOR antagonist nor-BNI, or 
the selective MOR antagonist cyprodime and assessed for approach behavior in the 
novel arena. The antagonist cyprodime significantly reduced approach latency, whereas 
morphine and nor-BNI were both ineffective. Moreover, antinociceptive studies with 
morphine confirmed MOR antagonist effects of cyprodime and revealed MOR antagonist 
properties of BPN 24 hr post-administration.  Interestingly, the combined treatment of 
naltrexone with BPN did not block BPN’s ability to reduce approach latency in the novel 
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arena. Altogether, these data support modulation of MOR activity as a key component of 
BPN’s antidepressant-like effects in the NIH paradigm.  
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Introduction 
 
Opioid receptors and their endogenous ligands are important modulators of neural 
pathways involved in the regulation of mood and emotional states (Lutz and Kieffer, 
2013a). The kappa opioid receptor (KOR) in particular is thought to contribute to the 
etiology of depression and anxiety (Bruchas et al., 2010). Exposure to stress increases 
expression of dynorphin, a neuropeptide that acts primarily at KORs (Shirayama et al., 
2004). Activation of KORs by dynorphin or a KOR agonist has been shown to elicit 
dysphoria and depressive-like behavior in rodents (Carlezon et al., 2006; McLaughlin et 
al., 2006c; McLaughlin et al., 2006a), whereas treatment with a selective KOR 
antagonist mitigates stress-induced affective behavior (Mague et al., 2003; McLaughlin 
et al., 2003; Carr et al., 2010). These preclinical findings have lent support to 
pharmacological modulation of the opioid system as a potential target for the 
development of novel antidepressants. Buprenorphine (BPN), a mixed-opioid drug, has 
emerged as a promising new candidate as an antidepressant drug. Clinical studies have 
shown low doses of BPN to be effective in alleviating depressive symptoms in treatment-
resistant patients and reducing suicidal ideation in severely suicidal patients (Bodkin et 
al., 1995b; Nyhuis et al., 2008; Yovell et al., 2015). Most notably, mood-elevating effects 
were observed within a couple weeks of treatment, in stark contrast to first-line 
treatments that often take 4-6 weeks to enhance mood.  
 BPN is a high affinity partial agonist at the MOR and an antagonist at the KOR. 
Preclinical studies have identified KOR antagonism as a potential mediator of BPN’s 
therapeutic effects in the FST (Almatroudi et al., 2015; Falcon et al., 2015). Whether 
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BPN’s effects at the MOR significantly contribute to its effects on other behavioral tests 
for antidepressant activity is not as well understood.  Our laboratory has previously 
shown that a single administration of low dose BPN ameliorates stress-induced 
suppression of approach behavior for palatable food when tested 24 h post-
administration (Falcon et al., 2015). The goal of the present study was to investigate the 
role of individual opioid receptors in mediating BPN’s restoration of conditioned 
approach behavior in the novelty-induced hypophagia test. To that end, we employed 
two approaches, genetic deletion and selective pharmacological modulation of opioid 
receptors, to distinguish the MOR from the KOR as the primary mediator of BPN’s 
effects in this paradigm. The results of this study show that BPN was effective in 
reducing approach latency in the novel arena in Oprk1-/- mice but not Oprm1-/- mice. 
Administration of the selective MOR antagonist cyprodime, but not the MOR agonist 
morphine or KOR antagonist nor-BNI, replicated the effects of BPN in the NIH test. 
Moreover, BPN’s effects were not blocked by combination treatment with naltrexone. 
These studies suggest a role for the MOR in mediating the antidepressant-like response 
of BPN in the NIH test as a behavioral measure of motivational conflict. 
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Materials and Methods 
 
Animals 
Male C57BL/6J mice, 7 weeks upon arrival and purchased from Jackson Laboratories 
(Bar Harbor, ME) were used for the majority of the studies. Male Oprm1-/- mice and 
littermate wild-type (WT) controls were generated using heterozygous breeding. Male 
Oprk1-/-  mice used in this study were generated from mating pairs of Oprk1-/- purchased 
from Jackson Laboratories and maintained via homozygous breeding. Male C57BL/6J 
mice, originally from Jackson Laboratories but generated within the colony, were used 
as their wild type (WT) controls because this was the background strain used in all of the 
genetic lines. Mice were housed up to 5 per cage (or in pairs for NIH experiments) in 
polycarbonate cages and maintained under a 12 h light-dark cycle (lights on at 0700 
hours) in a temperature (22 °C) and humidity-controlled environment. Food and water 
were available ad libitum. All experiments were approved by the Institutional Animal 
Care and Use Committee at the University of Pennsylvania. 
Drugs 
Buprenorphine hydrochloride (Sigma, St. Louis, MO and NIDA) and norbinaltorphimine 
(nor-BNI; Tocris Bioscience, Ellisville, MO) were administered at doses previously found 
to have antidepressant effects in C57BL/6J mice (Falcon et al., 2015). Doses of 
morphine sulfate (Spectrum Chemical, New Brunswick, NJ), U50,488 (Sigma), 
naltrexone hydrochloride (Sigma), and cyprodime hydrochloride (Tocris) were chosen 
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based on results from pilot studies investigating their antinociceptive effects. 
Buprenorphine and nor-BNI were dissolved in distilled water and injected 
intraperitoneally (i.p.). Morphine and naltrexone were dissolved in physiological saline 
and injected i.p. Cyprodime was dissolved in 1% ethanol and delivered by i.p. injection. 
Mice in the control groups were injected with vehicle or saline where appropriate. All 
doses were calculated according to the base weight of the drug and administered in a 
volume of 10 ml/kg. 
Hot plate test 
Mice were individually placed onto a hot plate heated to 55°C and enclosed by a 
Plexiglas container. The latency for the mouse to lick the hindpaw or jump was recorded. 
An 80-second cut-off was imposed to avoid tissue damage. The non-selective opioid 
antagonist naltrexone (1 mg/kg) (n = 6-7 per group) and selective MOR antagonist 
cyprodime (10 mg/kg) (n= 8-16 per group) were injected 1 hour prior to morphine or 
U50,488 administration and animals were tested 30 minutes later to determine the MOR 
and KOR antagonist properties of each drug. To assess the protracted effects of BPN on 
MOR activity, animals were examined for baseline antinociceptive response 24 hours 
after BPN (0.25 mg/kg) and then tested 30 minutes after morphine (10 mg/kg) 
administration (n = 9 per group). Data for this experiment is expressed as percentage of 
baseline (pre-morphine) response.   
Novelty-induced hypophagia (NIH) test 
Mice were pair housed and trained to eat a palatable food (three peanut butter chips 
presented in a small, clear petri dish) in a home feeding cage. Opaque, black, plastic 
dividers were placed inside each cage to separate the mice during home cage training 
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sessions. Mice were allowed to habituate to the dividers for 1 hr before the start of the 
training session. Animals were trained daily in 15-min sessions until they met the criteria 
of three consecutive days with approach latencies of 30 seconds or below. For novel 
cage testing, mice were placed in an empty, clear polycarbonate cage (25.5 × 46 × 20 
cm) with bright lighting (60 W light bulb) and scented with lemon (20% Lemon Joy 
solution). There was no food deprivation or habituation period prior to the novel cage 
test. The novel cage test session was videotaped, and the latency to approach during 
the 15-min test session was measured.  The approach latency was defined by the time it 
took the mouse to approach the dish in the center of the arena and begin feeding.  
In Experiment 1, mice were treated with BPN (0.25 mg/kg) immediately after their 
last training session and tested 24 hr later in the novel environment (n = 8-19 per group). 
Similarly, in Experiment 2 mice were injected with morphine (10 mg/kg) or nor-BNI (10 
mg/kg) and tested 24 hr later (n = 10-22 per group). In Experiment 3 mice were injected 
with cyprodime (10 mg/kg) 24 hr or 1 hr before testing (n = 10-25 per group). In 
Experiment 4, mice were either pre-treated with naltrexone (1 mg/kg) 1 hr before BPN 
(0.25 mg/kg) and tested 24 hr later or treated with naltrexone 24 hr after BPN and tested 
1 hr later (n = 9-19 per group).  
Data Analysis 
One-way and two-way ANOVAs were performed to determine the significance of 
differences between experimental groups. Significant overall main effects or interactions 
were followed by Holms-Sidak’s post hoc test. Unpaired two- tailed Student’s t tests 
were applied where appropriate. For all tests, p < 0.05 was considered statistically 
significant. Data are expressed as mean ± SEM.  
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Results 
	  
Effects of MOR and KOR disruption on BPN’s behavioral effects in the NIH test 
Acquisition of conditioned approach behavior to the palatable food was significantly 
diminished in Oprm1-/- mice (Figure 3.1).  Repeated measures two-way ANOVA 
revealed a significant main effect of genotype [F (2, 71) = 12.89, p < 0.001] and time [F 
(13, 923) = 89.57, p < 0.001], in addition to a significant genotype*time interaction [F (26, 
923) = 3.724, p < 0.001]. Between the second and tenth day of training Oprm1-/- took 
significantly longer to reach stable approach latencies compared to WT and Oprk1-/- 
mice (p < 0.05). A main effect of genotype was also observed in terms of days taken to 
reach criteria [F (2, 68) = 6.102, p = 0.004]. Oprm1-/- were slowest to meet the criteria of 
three consecutive days with approach latencies under 30 seconds (p < 0.01).  
 The behavioral effects of BPN (0.25 mg/kg) in the NIH test 24 h post-
administration were assessed in Oprm1-/-, Oprk1-/-, and WT mice (Figure 3.2). A 
significant genotype*treatment interaction was observed for latency to approach the food 
[F (2, 70) = 3.573, p = 0.033] and amount of food consumed [F (2, 69) = 3.882, p = 
0.025] in the novel arena. Post-hoc tests revealed BPN significantly reduced approach 
latencies and increased food consumption in WT (p < 0.05) and Oprk1-/- (p < 0.001) 
mice, but not Oprm1-/- mice.  
Effects of nor-BNI and morphine in the NIH test 24 h post-administration 
The effects of nor-BNI (10 mg/kg) and morphine (10 mg/kg) treatment on approach 
behavior in the NIH test 24 hr post-administration were assessed in WT animals (Figure 
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3.3). One-way ANOVA revealed no significant effects of treatment on approach latencies 
[F (2, 44) = 0.4651, p = 0.631] or food consumption [F (2, 44) = 1.972, p = 0.151]. 
Effect of selective MOR antagonist cyprodime in the NIH test 1 hr and 24 hr post-
administration 
The effects of cyprodime (10 mg/kg) treatment on approach behavior in the NIH test 1 h 
and 24 h post-administration was evaluated in WT animals (Figure 3.4). One-way 
ANOVA revealed a significant effect of treatment on latency to approach [F (2, 46) = 
7.710 P = 0.001 and food consumption F (2, 43) = 5.708 P = 0.006] in the novel arena. 
Cyprodime administered 1 hr prior to testing significantly reduced latency to approach 
the food reward (p < 0.01) and increased the amount of food consumed (p < 0.05). This 
effect was not observed when cyprodime was administered 24 hr prior to testing.  
 Cyprodime’s selectivity for MOR antagonism was confirmed using the hot plate 
test (Figure 3.5). One-way ANOVA revealed a significant effect of treatment on 
antinociceptive response [F (4, 46) = 7.513, p < 0.0001]. Antinociception was 
significantly increased in animals treated with morphine (10 mg/kg, p < 0.0001) or 
U50,488 (10 mg/kg, p < 0.05). Pre-treatment with cyprodime (10 mg/kg) significantly 
blocked antinociception induced by both morphine (p < 0.001), but not U50,488.  
Pharmacological blockade of opioid receptors does not block BPN’s behavioral effects in 
the NIH test.   
Next, we determined the effects of pharmacological blockade of opioid receptors on 
BPN’s behavioral effects in the NIH test (Figure 3.6). The effects of naltrexone (1 mg/kg) 
pre-treatment or post-treatment in combination with BPN (0.25 mg/kg) were measured in 
WT mice. Two-way ANOVA revealed a main effect of BPN [F (1, 70) = 11.20 P = 0.0013] 
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and naltrexone [F (2, 70) = 9.023 P = 0.0003] on approach latency in the NIH test. 
Treatment with naltrexone alone significantly reduced approach latency in the NIH test 
BPN’s ability to reduce latency to approach in the novel arena was not affected by either 
pre-treatment (1 hr prior to BPN administration, 24 hr prior to test) or post-treatment (24 
h after BPN administration, 1 hr prior to testing). Similarly, food consumption in the novel 
arena was increased by both BPN [F (1, 71) = 3.615, p = 0.0613] and naltrexone [F (2, 
71) = 8.421, p = 0.0005] regardless of time of naltrexone treatment.  
 The ability of naltrexone to effectively block MOR and KOR agonist activity was 
confirmed using the hot plate test (Figure 3.7). One-way ANOVA revealed a significant 
effect of treatment on antinociceptive response [F (4, 28) = 8.892, p < 0.001]. The 
latency for animals to lick their hindpaw was significantly increased in animals treated 
with the selective MOR agonist morphine (10 mg/kg, p < 0.001) or the selective KOR 
agonist U50,488 (10 mg/kg, p < 0.01). Pre-treatment with naltrexone (1 mg/kg) 
significantly blocked antinociception induced by both morphine (p < 0.001) and U50,488.  
Effect of BPN treatment on morphine-induced antinociception 24 hr post-administration 
BPN’s activity at the MOR 24 h post-administration was determined using the hot plate 
test (Figure 3.8). BPN (0.25 mg/kg) administered 24 h prior to morphine significantly 
reduced morphine-induced antinociception compared to vehicle treated animals (t = 
2.971, p < 0.01).   
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Discussion 
 
We report here for the first time two important findings concerning the pharmacological 
properties underlying BPN’s mechanism of antidepressant action and the involvement of 
the opioid system in mediating behavioral states etiologically relevant to human 
depression. First, utilizing animals with genetic knockdown of individual opioid receptors, 
we established that the effects of BPN in the NIH test are dependent on the MOR. 
Second, we demonstrate that BPN acts predominantly as a MOR antagonist at the time 
of testing (24 h post-administration), and that selective antagonism of the MOR is 
sufficient to alleviate the aversive effects of novelty on conditioned approach behavior for 
palatable food. Altogether, these data provide supportive preclinical evidence for the 
modulation of MOR activity as an integral component of BPN’s therapeutic effects.  
 The NIH test is a conflict-based paradigm that assesses stress-induced changes 
in motivational salience for a palatable food reward. Chronic treatment with selective 
serotonin reuptake inhibitors is reported to reduce approach latency for food in a novel 
environment in certain strains of rodents (Bodnoff et al., 1988; Bodnoff et al., 1989; 
Dulawa and Hen, 2005; Bechtholt et al., 2008). C57BL/6 mice, however, demonstrate a 
refractory response to SSRIs in this paradigm (Balu et al., 2009a; Robinson et al., 2016). 
Our laboratory has previously shown a single administration of low dose BPN to reduce 
novel arena approach latency in C57BL/6 mice when tested 24 hr post-administration 
(Falcon et al., 2015). This time point was chosen because BPN treatment induces MOR 
dependent hyperactivity in C57BL/6 mice that could obfuscate measures of behavioral 
output in the NIH test (Marquez et al., 2007; Falcon et al., 2015). Due to its complex 
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pharmacology (Lutfy and Cowan, 2004), the role of individual opioid receptors in 
mediating BPN’s behavioral response in the NIH test are not well understood. Thus, the 
primary aim of these studies was to systematically dissociate MOR versus KOR 
mediated mechanisms of action in the NIH paradigm.      
 The present study is the first to show that genetic deletion of MOR abolishes the 
behavioral effects of BPN in the NIH test. MORs are well known to play an important role 
in mediating the reinforcing properties of rewarding stimuli. Oprm1-/- mice fail to show 
conditioned place preference for drugs of abuse (Matthes et al., 1996; Kieffer and 
Gaveriaux-Ruff, 2002) in addition to reduced operant and hedonic responding for 
palatable food rewards (Papaleo et al., 2007). In the current study, Oprm1-/- mice 
displayed a marked deficit in acquiring conditioned approach behavior towards the 
peanut butter chips during training sessions. Interestingly, these animals did eventually 
develop stable approach latencies, suggesting that attribution of incentive salience to 
palatable food can occur independently of MOR activity, possibly through adoption of 
other feeding-related pathways (Menzies et al., 2013). Oprm1-/- and Oprk1-/- did not 
significantly differ from WT in their final baseline approach latency in the novel arena. 
Thus, the pure absence of individual receptors does not appear to mitigate the effects of 
stress in this paradigm. This is in contrast to previous studies that have reported 
increased behavioral resistance to stress in Oprk1-/- mice (Redila and Chavkin, 2008; 
Falcon et al., 2016a) and reduced anxiogenic behavior in Oprm1-/- mice (Filliol et al., 
2000). However, the present study is not directly comparable due to the differences in 
the behavioral tests measured. Interestingly, BPN efficacy in the NIH test was more 
pronounced in Oprk1-/- compared to WT mice. This may be due to compensatory 
upregulation of delta opioid receptors (Slowe et al., 1999), which have been shown to 
heterodimerize with MOR (Gomes et al., 2000).      
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 Pre-treatment with the non-selective opioid antagonist naltrexone did not alter 
behavioral response to BPN in the NIH test. Similarly, naltrexone administered 24 hr 
post BPN (1 hr prior to testing) did not block BPN’s effect on approach behavior in the 
novel arena. Naltrexone was administered at a dose experimentally confirmed to 
antagonize opioid activity at both the MOR and KOR. Thus, MOR activation by BPN is 
not required to obtain subsequent behavioral effects measured at 24 hr post-
administration. This was confirmed in a separate experiment showing that administration 
of morphine had no effect in the NIH test when assessed 24 hr post-administration. 
Interestingly, treatment with the KOR antagonist nor-BNI was also ineffective in reducing 
approach latency in the NIH test. Although this data corroborates our findings with 
knockout animals, it is contradictory to other studies demonstrating behavioral response 
to nor-BNI in the NIH test conducted in mice or rats (Almatroudi et al., 2015; Huang et 
al., 2016). This discrepancy may be attributed to differences in procedural execution or 
strain differences in behavioral response to KOR antagonists in this paradigm.  
 One of the more striking findings arising from the present study is that treatment 
with the selective MOR antagonist cyprodime was sufficient to reduce approach latency 
in the NIH test. Notably, cyprodime’s effects were observed 1 hr post-administration but 
not 24 hr post-administration, indicating acute, but not protracted, behavioral effects of 
this drug.  Studies conducted by Almatroudi et al. (2015) showed no behavioral effect of 
the irreversible MOR antagonist CCAM in the NIH test when administrated 48 hr prior to 
testing. However, CCAM may more closely model genetic deletion of MORs rather than 
the competitive blockade of MOR activity by cyprodime described here. Studies 
characterizing the antinociceptive effects of BPN have shown it to exhibit a rapid onset 
of action at the MOR followed by slow receptor dissociation, resulting in a prolonged 
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blockade of MOR for hours following injection (Cowan et al., 1977; Walker et al., 1995). 
In the present study we confirmed that pretreatment of BPN at the dose used in NIH 
testing antagonized the antinociceptive effects of morphine when tested 24 h post-
administration of BPN. Thus, the eventual blockade of MORs, as opposed to the brief 
period of MOR activation, likely mediates the protracted effects of BPN in the NIH test.  
 Given the role of MOR activation in mediating appetitive control, it is somewhat 
counterintuitive that blockade of MORs reinstated motivational behavior for palatable 
food. However, MORs are also known to modulate stress-induced changes in dopamine 
outflow in key brain regions involved in the processing of reward. Activation of MOR in 
the ventral tegmental area (VTA) has been shown to reduce dopamine transmission in 
the nucleus accumbens (NAc), a region highly implicated in the presentation of goal-
directed behavior (Berridge, 2012a; Latagliata et al., 2014). Moreover, local infusion of a 
MOR agonist into the central amygdala reduced open arm time in the elevated plus 
maze, suggesting a MOR mediated induction of anxiety-like behavior during exposure to 
novelty stress (Wilson and Junor, 2008). Thus, MOR activity may exert context-specific 
regulation of circuitries involved in reward processing, so as to promote reward-seeking 
behavior under basal conditions but not stressful conditions. Consequently, antagonism 
of MORs during exposure to acute stress may prevent stress-induced decreases in 
affective behavior.  
 In conclusion, these studies propose a novel mechanism of action for BPN’s 
antidepressant like effects in the novelty-induced hypophagia test, a behavioral measure 
of stress-induced motivational conflict. Utilizing genetic and pharmacological tools, we 
present a systematic approach to characterizing the role of opioid receptors in mediating 
affective behavior. The results of this study encourage further investigation into the 
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identification of neurobiological mechanisms underlying the effects of BPN in specific 
behavioral domains.  
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FIGURE 3.1 
 
 
 
Effect of genotype on home cage training. A) Oprm1-/- mice exhibited higher 
approach latencies compared to WT mice during training and B) took significantly longer 
to reach criteria compared to WT mice. n = 18-36 per group.  (* p < 0.05, **p < 0.01, *** 
p < 0.001, **** p < 0.00001 compared to WT).  Data is depicted as mean ± SEM. 
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FIGURE 3. 2 
	  
	  
BPN’s behavioral effects in the NIH test are blocked in Oprm1-/- mice. A). BPN 
reduced latency to approach and B) increased food consumed in WT and Oprk1-/- mice 
but not Oprm1-/- mice. n = 8-19 per group. (*p < 0.05, ***p < 0.001  compared to vehicle). 
Data are depicted as mean ±SEM.      	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FIGURE 3.3 
 
 
Treatment with morphine or nor-BNI does not affect behavior in the NIH test 24 h 
post administration. Treatment with a MOR agonist or KOR antagonist had no effect 
on A) approach latency in the NIH test or B) amount of food consumed in the novel 
arena. n = 10-22 Data are depicted as mean ±SEM.      
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FIGURE 3.4 
 
 
Treatment with cyprodime reduced approach latency in the NIH test 1 h post 
administration. Treatment with a MOR antagonist was sufficient to A) reduce approach 
latency and B) increase food consumption 1 h post administration but not 24 h post 
administration. n = 10-25. (**p < 0.01 compared to vehicle). Data are depicted as mean 
±SEM.      
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FIGURE 3.5 
 
 
Cyprodime selectively blocks morphine-induced antinociception. Pretreatment with 
cyprodime blocked morphine induced antinociception but not U50,488. n= 8 -16 per 
group. (*p < 0.05, ****p < 0.0001 compared to saline + vehicle, &p < 0.05 compared to 
saline + morphine). Data are depicted as mean ±SEM.      
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FIGURE 3.6 
 
 
Pharmacological blockade of opioid receptors does not block BPN’s behavioral 
effects in the NIH test.  A) Combination treatment of BPN and naltrexone reduced 
approach latency in the novel arena. Naltrexone given alone also reduced approach 
latency in the NIH test. B) Naltrexone treatment increased food consumption in the novel 
arena. n = 9-19. (**p < 0.01 compared to vehicle, ###p < 0.001 compared to saline). 
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FIGURE 3.7 
 
Naltrexone blocks morphine and U50,488-induced antinociception. Naltrexone 
pretreatment blocked antinociceptive effects of morphine and U50,488. n = 6-7 per 
group. (**p < 0.01, ***p < 0.001 compared to saline + saline, &&&p < 0.001 compared to 
saline + morphine, #p < 0.05 compared to saline + U50). Data are depicted as mean 
±SEM.      
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FIGURE 3.8 
 
 
Pretreatment with BPN blocks morphine-induced antinociception. (**p < 0.01 
compared to vehicle). n = 9 per group. Data are depicted as mean ±SEM.      
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Abstract 
	  
Both genetic background and pre-existing stress play critical roles in the effects of 
antidepressant drugs.  The current studies showed this principal by demonstrating that 
exposure to the stress hormone corticosterone (CORT) allowed behavioral and 
neurogenic effects to emerge following chronic treatment with fluoxetine of C57BL/6 
mice, a strain ordinarily resistant to these effects. Adult male mice were implanted 
subcutaneously with 21-day slow-release CORT pellets (10 mg) or placebo and then co-
treated with 5 mg/kg fluoxetine (b.i.d., i.p.) or saline for 14 days. Animals were then 
assessed for approach behavior in the novelty-induced hypophagia (NIH) test, 
hippocampal cell proliferation, corticosteroid receptor expression, and CORT plasma 
levels. Co-treatment of CORT with fluoxetine significantly reduced approach behavior in 
the novel environment of the NIH test and increased hippocampal cell proliferation 
whereas fluoxetine given alone was ineffective. CORT given alone did not alter 
approach behavior in the novel environment and caused a smaller increase of cell 
proliferation. The CORT effect was blocked by adrenalectomy and was likely due to 
increased adrenal feedback. Cell proliferation in CORT-treated animals was associated 
with reduced mineralocorticoid, but not glucocorticoid, receptor mRNA expression. 
Although the pellets were advertised to release CORT for 21 days, plasma CORT levels 
were increased at 1 day after implantation but were not sustained when measured at 7 
days or longer intervals. Nevertheless, the transient CORT increase was sufficient to 
induce long-lasting behavioral and molecular changes when followed by fluoxetine 
treatment. These studies warrant further investigation into the role of glucocorticoids and 
environmental stress as adjunctive facilitators of the response to antidepressants, 
especially for treatment-resistant patients.  
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Introduction 
 
Major Depressive Disorder (MDD) is one of the most common psychiatric disorders, with 
a lifetime prevalence of 17% in the United States and 4% worldwide (Kessler et al., 
2005; Eaton et al., 2008). In terms of years lost to disability, MDD is considered one of 
the most disabling medical conditions and is predicted to be a leading contributor to the 
worldwide burden of disease by 2030 (Mathers and Loncar, 2006). The majority of 
pharmacotherapies developed for the treatment of MDD target brain monoamine 
systems, primarily serotonin (5-HT), norepinephrine, and dopamine.  The most common 
of these, the selective serotonin reuptake inhibitors (SSRIs) and selective 
norepinephrine reuptake inhibitors (SNRIs), comprise a large proportion of 
pharmaceutical sales and are considered first line treatment for MDD. Unfortunately, an 
estimated 40% of patients fail to respond to these therapies (Cipriani et al., 2009; 
Culpepper, 2010). Further insight into the neurobiological mechanisms underlying 
antidepressant response is needed for the development of more efficacious 
antidepressant regimens.  
 The combination of genetic vulnerabilities and environmental factors, such as 
stress, are thought to be significant contributors to the onset of depression in humans 
(Charney and Manji, 2004). The likelihood of experiencing a depressive episode is 
greatly increased following a stressful life event or after accumulation of chronic minor 
stresses (Caspi et al., 2003; Harkness and Monroe, 2006). Moreover, many patients 
suffering from depression exhibit signs of dysfunctional hypothalamic-pituitary-adrenal 
(HPA) axis activity, as demonstrated by elevated basal cortisol levels and resistance to 
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dexamethasone, an exogenous steroid that suppresses cortisol in healthy individuals 
(Pariante and Miller, 2001b; Gillespie and Nemeroff, 2005). Interestingly, successful 
antidepressant treatment is often associated with restored suppression of HPA axis 
response (Schule, 2007). Together, these findings suggest a potential role of stress 
hormones, such as cortisol (corticosterone (CORT) in rodents), in the pathology and 
treatment of depression.  
 CORT produces its effects in the central nervous system via activation of 
glucocorticoid (GR) and mineralocorticoid  (MR) receptors. Though these receptors are 
ubiquitous throughout the brain, they are highly abundant in the hippocampus, where 
they provide crucial inhibitory feedback signals to the HPA axis (Sapolsky et al., 1984; 
Jacobson and Sapolsky, 1991). A reduction or absence of these inhibitory signals can 
promote hyperactivation of the axis and augmented secretion of glucocorticoids 
(Anacker et al., 2011; McEwen et al., 2012). In a healthy individual, elevated 
corticosteroid activity helps facilitate the physiological and behavioral adaptations 
required to appropriately respond to stressors and reinstate homeostasis. However, 
prolonged exposure to CORT can inhibit the proliferation and survival of adult-born 
hippocampal neurons, which have been shown to play an important role in the 
behavioral and neuroendocrine components of stress responses in rodents (Gould and 
Tanapat, 1999; Snyder et al., 2011). Conversely, chronic treatment of normal rodents 
with SSRIs, such as fluoxetine, increases hippocampal neurogenesis and neurotrophins 
such as brain derived neurotrophic factor (BDNF) (Duman and Monteggia, 2006; 
Schmidt and Duman, 2006; Krishnan and Nestler, 2008). Increased hippocampal 
neurogenesis is associated with behavioral indications of antidepressant efficacy in 
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rodents, such as reduced hyponeophagia and increased performance in the forced swim 
test (Dranovsky and Hen, 2006).  
 Our laboratory has previously shown that not all strains of mice respond to 
antidepressant treatments. Normal C57BL/6 mice are insensitive to the effects of chronic 
fluoxetine treatment, measured in the novelty-induced hypophagia (NIH) test, a conflict-
based test in which motivation to approach a highly palatable food is suppressed by a 
novel environment. Nor did C57BL/6 mice exhibit increase hippocampal cell proliferation 
in response to the antidepressant treatment (Balu et al., 2009a). In a small clinical study, 
Dinan et al. (1997) found that 4-day dexamethasone therapy significantly enhanced 
antidepressant response to SSRIs in treatment-resistant patients. Therefore, we 
hypothesized that activation of stress circuitry might be important to reveal the 
behavioral and neurogenic effects of fluoxetine in this non-responsive mouse strain.  
 CORT is a vital component of the central nervous system’s stress response 
circuitry. Although corticosteroids alone do not encompass all aspects of stress 
exposure (Belzung, 2014), previous studies have shown that chronic CORT exposure 
can induce a depressive-like motivational state in rodents that is similar to that produced 
by a chronic mild stress paradigm (Gourley et al., 2008). Moreover, CORT treatment 
alone is sufficient to alter molecular targets that are implicated in depression and 
antidepressant efficacy, such as hippocampal neurogenesis (Bilsland et al., 2006; 
Gourley and Taylor, 2009). In the current study we investigated the effects of exposure 
to commercial CORT pellets for 21 days in augmenting fluoxetine’s behavioral and 
proliferative effects in C57BL/6 mice. The results of this study showed that fluoxetine 
produced behavioral effects in the NIH test only in mice exposed to CORT. Furthermore, 
CORT administration with fluoxetine co-treatment augmented hippocampal cell 
	  108	  
	  
proliferation, an effect potentially mediated by alterations in hippocampal corticosteroid 
receptor expression. Interestingly, analysis of plasma at the end of treatment revealed a 
paradoxical decrease in CORT levels in animals treated with the pellets, suggesting that 
the CORT pellets did not work as advertised. Adrenalectomized animals implanted with 
CORT pellets revealed a sharp drop in CORT plasma levels by day 7 of treatment, 
indicating that this method of CORT exposure produced transiently elevated, but not 
sustained, CORT levels. Nevertheless, these experiments revealed the important finding 
that CORT exposure potentiates the behavioral and neurogenic effects of chronic 
fluoxetine administration in a mouse strain that is otherwise non-responsive to this 
antidepressant treatment.  
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Materials and Methods 
 
Animals 
Intact and adrenalectomized male C57BL/6J, 7-8 weeks old upon arrival, were 
purchased from Jackson Laboratories (Bar Harbor, ME). Mice were housed in groups of 
4 (except for those used in the NIH test whom were housed in in pairs) in polycarbonate 
cages and maintained on a 12 hour light-dark cycle (lights on at 0700 hours) in a 
temperature (22 °C)- and humidity-controlled environment. Food and water were 
available ad libitum. All experiments were approved by the Institutional Animal Care and 
Use Committee at the University of Pennsylvania.  
Experimental Design 
Experiment 1: Intact animals were implanted with CORT pellets (10 mg) or placebo 
pellets. Beginning on day 7 of CORT treatment, animals were dosed with either 
fluoxetine (5 mg/kg b.i.d., i.p.) or saline daily for the remaining 14 days of the 
experiment. Cohort 1: Animals were tested in the NIH and home cage test on the last 
two days of drug treatment (n =8-10 per group). Cohort 2: Animals received a single 
injection of BrdU on the last day of drug treatment and were sacrificed 24 hours later. In 
these animals hippocampal tissue was dissected and analyzed for BrdU positive cells 
and corticosteroid mRNA expression. Trunk blood was collected at time of sacrifice and 
analyzed for plasma CORT levels (n = 15-19 per group). 
Experiment 2: Adrenalectomized animals were implanted with CORT pellets (10 mg) or 
placebo pellets and received chronic fluoxetine treatment as described in Experiment 1.  
All mice received additional CORT replacement through the drinking water (25 µg/ml in 
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0.9% saline) to prevent the loss of electrolyte homeostasis (Funder, 2006) and eliminate 
the confounding effects of adrenalectomy alone on neurogenesis (Cameron and Gould, 
1994). Animals received a single injection of BrdU on the last day of drug treatment and 
were sacrificed 24 hours later. Hippocampal tissue was dissected and analyzed for BrdU 
positive cells (n =7-10 per group).  
Experiment 3: Intact animals were implanted with CORT pellets (2.5 mg) or placebo 
pellets and received chronic fluoxetine treatment as described in Experiment 1. Animals 
received a single injection of BrdU on the last day of drug treatment and were sacrificed 
24 hours later. Hippocampal tissue was dissected and analyzed for BrdU positive cells 
(n = 9-10 per group).  
Experiment 4: Adrenalectomized animals were implanted with CORT pellets (10 mg) or 
placebo pellets and then sacrificed 1, 7, 14, or 21 days after implantation. Trunk blood 
was collected at time of sacrifice and analyzed for plasma CORT levels (n = 5-6 per 
group).  
Drug Formulation 
CORT pellets (2.5 mg and 10 mg, 21 day release, Innovative Research of America, 
Sarasota, FL, USA) were composed of a proprietary matrix of cholesterol, cellulose, 
lactose, phosphates and stearates designed to facilitate continuous and sustained 
diffusion of CORT over a period of 21 days. Placebo pellets consisted of the same 
matrix without the active product. Fluoxetine hydrochloride  (5 mg/kg; Anawa, Zurich) 
was dissolved in distilled water and delivered by intraperitoneal (i.p.) injection in a 
volume of 10 ml/kg. Fluoxetine was administered twice daily because, due to its half-life, 
this dosing strategy results in relatively stable plasma levels (Hodes et al., 2010) and 
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occupation of brain serotonin transporters (Hirano et al., 2004). Control animals received 
saline (0.9% NaCl).  5-Bromo-deoxyuridine (BrdU; Roche Applied Sciences Indianapolis, 
IN) was dissolved in warm saline at a dose of 200 mg/kg and administered i.p. in a 
volume of 10 ml/kg.  
Novelty Induced Hypophagia (NIH) Test 
Mice were pair housed and trained to eat a palatable food (three peanut butter chips 
presented in a small, clear petri dish) in a home cage environment. Animals were trained 
daily in 15-minunte sessions until they met the criteria of three consecutive days with 
approach latencies of 30 seconds or less. Opaque, black, plastic dividers were placed 
inside each cage to separate the mice during training of home cage training sessions. 
Mice were allowed to habituate to the dividers for 1 hour before the start of the training 
session. Once all animals had met criteria, training sessions were suspended and drug 
treatments were initiated.  Three days before novel testing all animals were re-exposed 
to the peanut butter chips through additional training sessions. For novel cage testing, 
peanut butter chips were presented in the center of an empty, clear polycarbonate cage 
(25.5 × 46 × 20 cm) with bright lighting (60 W light bulb) and scented with lemon (20% 
Lemon Joy solution). Novel cage testing was videotaped. Mice were placed into the test 
cage and the latency to approach during the 15-minute test session was measured. The 
approach latency was defined as the time to ingestion. There was no food deprivation or 
habituation period prior to the novel cage test. All behavioral testing took place during 
the light phase. The home cage test was performed the day after the novel cage test. 
BrdU Incorporation Using Flow Cytometry 
Flow cytometry is a frequently used method for analyzing newly dividing cells in the 
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hippocampus. This method has been previously validated by our lab and others, and 
compared to results obtained from immunostaining (Bilsland et al., 2006; Balu et al., 
2009b; Spoelgen et al., 2011). BrdU labeling was measured in cells displaying the 
nuclear marker 7-aminoactinomycin D (7-AAD) by flow cytometry as previously 
described (Balu et al., 2009b).  Briefly, mice were decapitated 24 hours following BrdU 
injection, their brains quickly removed, and the hippocampus dissected. Hippocampal 
tissue was manually minced, digested using an enzymatic mixture (1 mg/ml papain, 
Roche Applied Science; 0.1 M L-cysteine, Sigma-Aldrich, St. Louis, MO), and then 
mechanically triturated to form a single cell suspension. Cells were fixed, permeabilized, 
and stained using the flourescein isothiocyanate (FITC) BrdU Flow Kit (BD Biosciences, 
San Jose, CA). Data were collected on the same day using a BD FACS Canto System 
(BD Biosciences) at the University of Pennsylvania Flow Cytometry Core Facility. 
Background signals were controlled for by collecting data from a BrdU-free control. All 
data were analyzed using BD FACSDiva Software (BD Biosciences).  
Analysis of corticosteroid receptor expression using quantitative real-time polymerase 
chain reaction (qRT-PCR) 
RNA was extracted with Trizol reagent (Gibco BRL, Life Technologies, NY) and purified 
using the RNeasy Mini Kit  (Qiagen, Valencia, CA) following the manufactures’ 
instructions. RNA concentrations were measured and 300 ng/µl RNA was used as a 
template to synthesize c-DNA using the Superscript Vilo c-DNA Synthesis kit (Invitrogen, 
Carlsbad, CA, USA). All reactions were performed with a master mix of SYBR green 
(Applied Biosystems, Austin, TX) and 300 nM primers (final concentration). Quantitative 
real-time polymerase chain reactions (qRT-PCR) were run using the Stratagene 
MX3000 and MXPro QPCR software. Cycling parameters were as follows: 95°C for 10 
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min, 40 cycles at 95°C (30 s) and 60°C (1 min), ending with a melting curve analysis to 
control for amplification. All reactions were performed in triplicate and the mean cycle 
threshold was used for analysis. The mRNA levels of target genes were normalized to 
the house- keeping gene TATA binding protein (TBP) using the 2Δct method. Primer 
sequences are available upon request.  
Analysis of plasma CORT using enzyme-linked immunosorbent assay (ELISA)  
Trunk blood was collected at time of sacrifice, which occurred between 8-10 am for all 
experiments. Blood was stored in 0.5 mL heparin and centrifuged at 3000 rpm for 20 
minutes. Plasma was removed and stored frozen (–80º C) until analysis. The amount of 
CORT in the plasma from each sample was measured in duplicate by ELISA following 
the manufactures instructions (Immunodiagnostic Systems, Fountain Hills, AZ). Intra-
assay variability for the CORT kit ranged from 5.9%-7.0%, inter-assay variability ranged 
from 8.2-8.9%; mean assay sensitivity was 0.17 ng/ml.  
Data Analysis  
One-way and two-way ANOVA were performed to examine the significance of 
differences between treatments. Significant overall main effects (p < 0.05) or interactions 
showing a trend (p < 0.10) were followed by Tukey or Bonferroni post-hoc tests. For all 
follow-up tests, p < 0.05 was considered statistically significant.  Data are expressed as 
mean ± SEM.
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Results 
 
The effects of 10 mg CORT pellet exposure and fluoxetine treatment on behavior 
 
Mice were randomly assigned to either placebo or CORT pellet exposure, and then 
further separated into either saline or fluoxetine treatment groups. As seen in Figure 
4.1A, a two-way repeated measures ANOVA revealed a significant interaction [F(9,102) 
= 3.761, p < 0.001] and main effect [F(3,102) = 12.68, p < 0.001] of time on body weight 
during drug treatment. Placebo-treated animals exhibited significant weight gain by day 
14 (p < 0.05). Although CORT-exposed animals failed to gain weight within the initial 7 
days of treatment, animals subsequently treated with fluoxetine showed significant 
weight gain by day 21 (p < 0.001) whereas saline treated animals continued to show 
inhibited weight gain. The overall change in body weight (from day 1 to day 21) shown in 
Figure 4.1B illustrates a significant main effect of treatment with fluoxetine [F(1, 34) = 
8.830, p < 0.01]. 
The behavioral effects of CORT and fluoxetine treatment were then measured in 
the NIH test. Exposure to a novel environment increased approach latency [F(1,65) = 
972.4, p < 0.0001] and reduced the amount of food consumed [F(1,68) = 136.0, p < 
0.0001]  compared to home cage in all treatment groups. There was a significant 
interaction between CORT exposure and fluoxetine treatment in approach latencies in 
the novel environment [F(1,33) = 8.041, p < 0.01]. CORT-exposed animals treated with 
fluoxetine displayed significantly lower approach latencies compared to CORT-exposed 
animals treated with saline. Moreover, fluoxetine treatment had no effect on approach 
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latency in placebo-treated animals in the novel environment (Figure 4.2A). There were 
no significant differences in food consumption in the novel environment between drug 
treatment groups (Figure 4.2B). In the home cage, CORT treatment significantly reduced 
latency to approach [F(1, 33) = 4.772, p < 0.05] and increased the amount of food 
consumed compared to placebo treated animals [F(1, 34) = 4.956, p < 0.05] (Figure 
4.2C and 4.2D). 
 
The effects of 10 mg CORT pellet exposure and fluoxetine treatment on hippocampal 
cell proliferation, CORT plasma levels and corticosteroid receptor expression 
In a separate cohort, animals received a single injection of BrdU on the last day of drug 
treatment and were sacrificed 24 hours later. Hippocampal tissue was analyzed for BrdU 
positive cells and corticosteroid mRNA expression. Additionally, trunk blood was 
collected at time of sacrifice and analyzed for plasma CORT levels. As seen in Figure 
4.3A, flow cytometric analysis of hippocampal tissue revealed that in placebo treated 
animals, fluoxetine had no effect on hippocampal cell proliferation. Interestingly, CORT-
exposure significantly increased hippocampal cell proliferation compared to placebo 
treated animals [F(1,59) = 50.87, p < 0.001]. Moreover, there was a significant 
interaction between CORT exposure and fluoxetine treatment on neurogenesis [F(1, 59) 
= 6.702, p < 0.05]. Post hoc multiple comparisons revealed that CORT-exposed animals 
treated with fluoxetine displayed significantly higher hippocampal cell proliferation 
compared to CORT-exposed animals treated with saline.  
Analysis of circulating CORT levels at the time of sacrifice revealed that 
exposure to CORT pellets significantly reduced CORT plasma levels in both saline and 
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fluoxetine treated animals by approximately 50% when measured on day 21 [F(1, 66) = 
36.06, p < 0.001] (Figure 4.3B). Fluoxetine treatment did not alter CORT levels.  
Glucocorticoid (GR) and mineralocorticoid (MR) receptor transcription was 
examined in the hippocampus as a potential molecular mechanism underlying the 
CORT-induced neurogenic response to fluoxetine in C57BL/6 mice. There was no 
significant effect of CORT or fluoxetine on GR mRNA expression (Figure 4.3C). 
However, exposure to CORT significantly reduced hippocampal MR mRNA expression 
in both saline and fluoxetine treated animals [F(1,68) = 4.276, p < 0.05] (Figure 4.3D). 
The effects of adrenalectomy on 10 mg CORT pellet exposure induced hippocampal cell 
proliferation  
To investigate the mechanisms underlying the increase in hippocampal cell 
proliferation by CORT pellets, adrenalectomized animals were used to examine the 
effects of 10 mg CORT pellet exposure and fluoxetine treatment on hippocampal 
neurogenesis in the absence of adrenal feedback. There was a significant main effect of 
CORT on cell proliferation [F(1, 30) = 5.298, p < 0.05] and a trend towards an interaction 
[F (1, 30) = 3.372 p = 0.08]. As illustrated in Figure 4.4A, adrenalectomized CORT-
exposed animals treated with fluoxetine, but not saline, displayed a significant two-fold 
increase in cell proliferation compared to placebo treated animals (p < 0.05). However, 
CORT treatment did not increase cell proliferation in adrenalectomized animals.   
The effects of 2.5 mg CORT pellet exposure and fluoxetine treatment on hippocampal 
cell proliferation  
We next examined whether a lower dose of CORT pellet exposure combined with 
fluoxetine treatment would induce an increase in hippocampal neurogenesis in intact 
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animals. There was a significant main effect of CORT pellet exposure [F(1, 35) = 6.477, 
p < 0.05] and a significant interaction between CORT pellet exposure and fluoxetine 
treatment [F(1, 35) = 4.705, p < 0.05] on hippocampal cell proliferation. As shown in 
Figure 4.4B, CORT-exposed animals treated with saline exhibited a significant increase 
in cell proliferation compared to placebo treated animals, as in prior studies. In contrast, 
the lower dose of CORT pellet was incapable of increasing hippocampal cell 
proliferation.   
Evaluation of the sustained effects of 10 mg CORT pellet treatment on plasma CORT 
levels  
To determine whether 10 mg CORT pellets maintain elevated plasma CORT levels for 
the advertised duration, adrenalectomized animals were implanted with 10 mg CORT 
pellets on day 0 and, CORT plasma levels were assessed on day 1, 7, 14, and 21 post-
implantation.  As shown in Figure 4.5, plasma CORT levels changed dramatically over 
time (F(3,19) = 16.18, p < 0.01), and were no longer in the supraphysiological range by 
the seventh day of CORT pellet exposure.   
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Discussion 
 
Activation of stress circuitry from implanted CORT pellets produced behavioral and 
neurogenic effects from chronic fluoxetine treatment in a strain of mice that would 
otherwise have been unresponsive to the effects of the antidepressant. Specifically, co-
treatment of CORT with fluoxetine significantly reduced the effects of novelty stress 
measured on approach behavior in the NIH test and increased hippocampal cell 
proliferation. These two effects of antidepressant treatment have been linked together 
because the behavioral response to fluoxetine is blocked in mice that cannot increase 
hippocampal cell proliferation (Sahay and Hen, 2007). Although treatment with CORT 
alone unexpectedly increased cell proliferation to a lesser extent, this effect was absent 
in adrenalectomized mice while the augmented combination treatment effect was 
preserved. Measurement of plasma CORT levels revealed that the CORT pellet did not 
maintain elevated levels for more than a few days, even though it was expected to be 
active for 21 days, suggesting that the impact of the CORT treatment was likely the 
after-effect resulting from the supraphysiological levels of acute exposure. Overall, these 
findings reveal potential neurobiological mechanisms underlying effective antidepressant 
response in a unique model of treatment resistance.  
Hyponeophagia, the unconditioned suppression of feeding in a novel 
environment, is a behavioral measure of stress that may be sensitive to the anxiolytic 
effects of chronic, but not acute, antidepressant treatment with SSRIs (Bodnoff et al., 
1988; Bodnoff et al., 1989; Dulawa et al., 2004; Dulawa and Hen, 2005; Bechtholt et al., 
2007). Fluoxetine’s effect of reducing approach latency to food in a novel environment is 
abolished after focal irradiation of the hippocampus or genetic deletion of hippocampal 
precursor cells, indicating that hippocampal neurogenesis is a necessary component of 
	  119	  
	  
this behavioral antidepressant response (Santarelli et al., 2003; Surget et al., 2008; 
Wang et al., 2008; David et al., 2009). Intriguingly, unlike other mouse strains, C57BL/6 
mice did not exhibit reduced hyponeophagia or increased hippocampal neurogenesis 
following chronic fluoxetine treatment (Balu et al., 2009a). However, in the present study, 
we showed that CORT-exposure via pellet implantation induced a behavioral response 
to fluoxetine in the NIH test in this unresponsive strain. Moreover, CORT-exposure in 
combination with fluoxetine treatment produced a robust increase in hippocampal 
neurogenesis that was not seen in placebo treated animals. Although correlative, the 
increased behavioral response to chronic fluoxetine treatment in CORT-treated mice 
could be attributed to heightened hippocampal cell proliferation.  
Stress is a well-established robust inhibitor of adult neurogenesis (Gould and 
Tanapat, 1999; McEwen et al., 2012). Similarly, CORT exposure alone has been shown 
to be a negative regulator of hippocampal neurogenesis (Cameron and Gould, 1994; 
Wong and Herbert, 2004; Bilsland et al., 2006; Murray et al., 2008; Brummelte and 
Galea, 2010). Reduced hippocampal cell proliferation typically coincides with increased 
plasma CORT levels, signifying that circulating CORT levels at the time of testing 
underlie CORT-induced changes in proliferation (Wong and Herbert, 2006). 
Paradoxically, we observed dramatically reduced plasma CORT levels in all CORT-
exposed animals following the 21-day pellet treatment, while hippocampal cell 
proliferation was increased. We suspected this might have been due to unanticipated 
changes in adrenal function.  The adrenals operate through an inhibitory feedback 
system in which increased circulating CORT levels serve as a signal for reduced 
synthesis and secretion from the adrenals (Sapolsky et al., 1984; Herman and Cullinan, 
1997). CORT pellet treatment may have increased internal negative feedback to the 
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point of adrenal inactivation, resulting in reduced endogenous circulating CORT levels 
and disinhibition of cell proliferation. To test for this we examined the effects of CORT 
pellet and chronic fluoxetine co-treatment on hippocampal cell proliferation in 
adrenalectomized animals.  Notably, in the absence of adrenal feedback, CORT-
exposed animals treated with saline did not demonstrate increased neurogenesis 
whereas those given fluoxetine still exhibited a proliferative response. Therefore, the 
mechanisms underlying the augmented neurogenic effect seen in combination treated 
animals cannot be attributed to artifacts of adrenal feedback. It is important to note, 
however, that adrenalectomized animals in all treatment groups were supplemented with 
a low dose CORT-treatment (25µg/ml) delivered via drinking water. This mode of 
delivery produces small rhythmic changes in plasma CORT levels, which have been 
shown to be necessary for fluoxetine-stimulated neurogenesis in rats (Huang and 
Herbert, 2006). It is possible, then, that rhythmic fluctuations in CORT levels modulate 
sensitivity to the proliferative effects of fluoxetine. In spite of this, adrenalectomized 
placebo animals treated with fluoxetine did not exhibit increased proliferation, 
demonstrating that supplemental CORT alone was not sufficient to induce a neurogenic 
response to fluoxetine. 
To determine whether a lower dose of CORT could elicit a neurogenic response 
in the presence of fluoxetine without increasing proliferation on its own, we evaluated 
hippocampal cell proliferation in intact animals treated with 2.5 mg CORT pellets. Similar 
to the 10 mg CORT pellet treatment, exposure to 2.5 mg CORT pellet treatment 
produced elevated cell proliferation. However, there was no additional effect in the 
presence of fluoxetine, suggesting that this dose is sufficient to produce CORT-induced 
increases in neurogenesis, but not sufficient to elicit an augmented proliferative 
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response when combined with fluoxetine. This finding is in contrast to David et al. (2009) 
who showed a low dose of 5 mg/kg/day CORT treatment to be effective in reducing 
hippocampal cell proliferation alone and stimulating proliferation when paired with 
fluoxetine treatment in C57BL/6 mice. However, whereas the current study utilized a 
three-week CORT pellet treatment, David and colleagues had CORT delivered though 
drinking water and animals were treated for a substantially longer period of time (7 
weeks). Therefore, rhythmic low dose CORT treatment over a longer period of time may 
be sufficient to increase neuronal sensitization to fluoxetine in this strain.  
Hippocampal MRs and GRs play a vital role in mediating stress responsiveness. 
Altered corticosteroid activity can dysregulate the stress response system and enhance 
the risk of development of stress-related disorders (Groeneweg et al., 2012). On the 
other hand, synergistic interactions between hippocampal corticosteroid receptors and 
serotonergic signaling pathways may mediate the effects of CORT exposure on 
enhancing the neurogenic responses to fluoxetine in C57BL/6 mice. For example, CORT 
treatment has been shown to facilitate fluoxetine-induced enhancement of dopaminergic 
modulation at the mossy fiber synapse (Kobayashi et al., 2013).  
Consistent with recent findings, CORT treatment reduced hippocampal MR 
expression while having no effect on GR expression (Saenz del Burgo et al., 2013), 
suggesting that MR expression is more sensitive to the effects of CORT exposure. This 
may be due to the fact that MRs exhibit 10-fold higher affinity for CORT compared to 
GRs (Joels et al., 2008). Hippocampal MRs selectively contribute to neuronal stability 
and excitatory tone and have been shown to mediate behavioral reactivity to a novel 
environment (Oitzl et al., 1994; Berger et al., 2006), hence changes in MR expression 
and function are likely to impact both hippocampal plasticity and associated behaviors. 
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Interestingly, in the current study, MR expression was similar between CORT-exposed 
animals treated to either saline or fluoxetine treated, indicating that variations in 
expression alone cannot explain the augmented behavioral and neurogenic responses 
seen in CORT-exposed animals treated with fluoxetine. However, it is important to note 
that MR and GR expression exhibit a diurnal regulation that is modulated by circulating 
CORT levels (Herman et al., 1993; Holmes et al., 1995). Since exogenous CORT 
treatment has been reported to flatten the natural circadian rhythm of plasma CORT 
(Leitch et al., 2003), CORT pellet exposure could potentially alter rhythmic MR and GR 
occupancy throughout the day. Thus, the observed neurogenic effects of CORT and 
fluoxetine treatment might be mediated by changes in circadian expression of MR and 
GRs. Further studies are needed to confirm this.  
 A major caveat of this study is the lack of sustained CORT release from the pellet 
treatment. CORT pellets have been used to model chronically elevated CORT levels, a 
physiological indicator of dysregulated HPA axis functioning and risk factor for the onset 
of MDD (Goodyer et al., 2010; Owens et al., 2014). On the contrary, we found that 
CORT plasma levels dropped precipitously between day 1 and day 7 of CORT pellet 
treatment. Rather than a sustained release, the CORT pellets produced a rapid, but 
short-lived, elevation of CORT during the initial days of exposure and then became 
inactive, resulting in CORT levels falling to the normal physiological range at the time of 
the experimental studies.  Similar findings were reported in another study evaluating the 
performance of pellets designed to release CORT for 7 days in birds. Muller et al. (2009) 
found that CORT plasma levels peaked 1-2 days after pellet implantation and reached 
placebo levels by day 3. The authors posited that the pellets, being originally designed 
for rodents, are not as effectively metabolized in other species. However, our data 
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corroborate the findings that the CORT pellets do not reliably produce sustained CORT 
release for the indicated length of treatment. In light of this, slow-release CORT pellets 
are not appropriate for modeling prolonged elevated CORT levels.  Instead, these pellets 
may more closely model the effects of exposure to a strong acute stressor, as with post-
traumatic stress disorder. Interestingly, the initial surge in CORT levels during the first 
few days of treatment was sufficient to induce long lasting molecular and behavioral 
changes in treated animals, suggesting that alterations in CORT levels, not necessarily 
at a pathological level, can impact the efficacy of fluoxetine.  
 In conclusion, this study found that exposure to exogenous CORT increases 
behavioral and neurogenic sensitivity to chronic fluoxetine treatment in C57BL/6 mice, a 
typically non-responsive strain of mice. These data recapitulate the general findings that 
genetic background and environment play a fundamental role in antidepressant 
response.  Although slow-release CORT pellets did not model the effects of sustained 
elevated CORT exposure as anticipated, these studies effectively indicate that CORT 
exposure is sufficient to reveal the anxiolytic and neuroplastic effects of chronic 
fluoxetine treatment in a typically unresponsive strain and could model an augmentation 
strategy for treatment-resistant patients. These findings implicate corticosteroid receptor 
activity and modulation as a potential variable in the stratification of antidepressant 
response in patients with MDD and possibly as a mediator of the effects of 
environmental stress on the effects of antidepressants.  
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FIGURE 4. 1 
 
Effects of 10 mg CORT pellet and fluoxetine treatment on weight gain. SAL = 
Saline, FLX = Fluoxetine, CORT = Corticosterone. Arrow denotes start of fluoxetine 
treatment.  A) Weight change over time in each treatment group. Placebo treated 
animals gained weight over time. CORT/SAL animals displayed inhibited weight gain 
whereas CORT/FLX animals showed normal weight gain after beginning FLX treatment. 
Symbols represent significant differences compared to day 1: a (PLACEBO/FLX, p < 
0.05)  b (PLACEBO/SAL, p <0.01)  c (CORT/FLX, p < 0.01)  (B) Overall weight change 
(from day 1 to day 21) showed that fluoxetine treatment increased weight gain in both 
placebo and CORT treated animals (n = 9-10 per group). Data is depicted as mean ± 
SEM. ##p < 0.01 within placebo or CORT treated groups. 
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FIGURE 4. 2 
 
 
Effects of 10 mg CORT pellet and fluoxetine treatment in the novelty induced 
hypophagia test. SAL = Saline, FLX = Fluoxetine, CORT = Corticosterone. A) 
Fluoxetine significantly reduced approach latency in the novel arena in animals exposed 
to CORT, but not placebo. B) There was no effect of treatment on amount consumed. C) 
In the home cage, CORT exposure significantly reduced latency to approach and D) 
increased the amount of food consumed (n = 8-10 per group). Data is depicted as mean 
± SEM. #p < 0.05 within CORT treated groups, *p < 0.05 between placebo and CORT 
treated groups. 
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FIGURE 4.3 
 
Effects of 10 mg CORT pellet and fluoxetine treatment on hippocampal cell 
proliferation, CORT plasma levels, and hippocampal corticosteroid receptor 
expression. SAL = Saline, FLX = Fluoxetine, CORT = Corticosterone. A) Values are 
expressed as the number of BrdU-positive cells per 10,000 7-AAD events. Intact animals 
exhibited a significant increase in hippocampal cell proliferation after treatment with 
CORT. This effect was further augmented in CORT-exposed animals treated with 
fluoxetine. Fluoxetine had no effect in placebo treated animals (n = 14-18 per group). B) 
CORT treatment significantly reduced plasma CORT levels. Fluoxetine had no additive 
effect on CORT levels (n = 15-19 per group). C) CORT had no effect on hippocampal 
GR mRNA expression but (D) reduced hippocampal MR mRNA expression (n = 15-19 
per group). Data is depicted as mean ± SEM. ###p < 0.001 within CORT treated groups, 
***p < 0.001, *p < 0.05 between placebo and CORT treated groups. 
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FIGURE 4. 4 
 
Effects of adrenalectomy or low dose CORT exposure on hippocampal cell 
proliferation. SAL = Saline, FLX = Fluoxetine, CORT = Corticosterone. A) Values are 
expressed as the number of BrdU-positive cells per 10,000 7-AAD events.  In 
adrenalectomized animals exposed to 10 mg CORT pellets, fluoxetine produced an 
increase in proliferation. (n = 7-9 per group. B). In intact animals exposed to 2.5 mg 
CORT pellets, hippocampal cell proliferation was increased, but not further augmented 
by fluoxetine (n = 9-10 per group). Data is depicted as mean ± SEM. #p < 0.05 within 
CORT treated groups, *p < 0.05 between placebo and CORT treated groups. 
 
	  128	  
	  
FIGURE 4.5 
 
Effects of CORT pellet on plasma CORT levels over time. Adrenalectomized animals 
implanted with 10 mg CORT pellets displayed significantly reduced CORT plasma levels 
after 7 days of treatment. (n = 5-6 per group). Data is depicted as mean ± SEM.  
Absolute mean values are:  247.2 ± 43.92, 20.8 ± 7.02, 34.7 ± 24.44 and 37.6 ± 16.32 
ng/ml.  ****p < 0.0001, ***p < 0.001 compared to day 1. 
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Summary of findings 
 
Efforts to elucidate the pathophysiological underpinnings of depression have been 
hindered by the heterogeneous classification of the disease. The Research Domain 
Criteria (RDoC) initiative (Cuthbert, 2014) spearheaded by the National Institute of 
Mental Health has called for the deconstruction of psychiatric syndromes into key 
components that can be mapped onto physiological processes. Deficits in motivational 
and hedonic processing are a hallmark symptom of depression. Moreover, they are 
more prevalent in individuals with a history of excessive stress exposure during 
childhood or early development. These observations support exposure to stress as a 
critical mediator in the development of depressive phenotypes. Because of the 
importance of the nexus between stress and reward, the goal of this thesis research was 
to further examine the intersection of brain stress and reward circuitry in the 
manifestation and treatment of motivational deficits that contribute to behavioral 
phenotypes related to depression.  
The research presented in this thesis first characterized the neural substrates 
underlying conditioned approach behavior for palatable food, revealing a critical role for 
nucleus accumbens (NAc) dopamine (DA) transmission in the acquisition and 
maintenance of motivational output for a palatable food reward in mice. These findings 
were further expanded to show that exposure to acute stress, as modeled in the novelty-
induced hypophagia (NIH) paradigm, diminished approach behavior and blunted the DA 
response to palatable food. Pretreatment with the mixed opioid drug buprenorphine 
prevented the neurochemical and behavioral effects of the stressor, thus identifying the 
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brain opioid system as a potential pharmacological target for mitigating the aversive 
effects of stress on incentive salience for natural rewards. This hypothesis was further 
explored by investigating the role of individual opioid receptors in mediating restoration 
of conditioned approach behavior in the novelty-induced hypophagia test, leading to the 
novel finding that selective antagonism of the mu opioid receptor is sufficient to alleviate 
suppressed approach behavior. Lastly, an exogenous corticosterone (CORT) 
administration paradigm was employed to examine the interaction between stress 
hormones and antidepressant treatment on approach behavior in the NIH paradigm. 
Remarkably, CORT treatment potentiated the behavioral effects of the selective 
serotonin reuptake inhibitor fluoxetine in a mouse strain that is otherwise non-responsive 
to this antidepressant treatment. Altogether, these findings expand our understanding of 
how stress impacts neurobiological processes involved in the expression of goal-
directed behaviors. Simultaneously, these findings identify novel pharmacological targets 
and strategies for the treatment of depressive phenotypes characterized by anhedonia.  
NAc DA as a neural underpinning of incentive salience  
 
Multiple lines of evidence support the involvement of the mesocorticolimbic DA system, 
specifically the nucleus accumbens (NAc), in the processing of the reward value of a 
stimulus. Animals will operantly respond for NAc infusions of agents that increase 
extracellular DA (Hoebel et al., 1989; Phillips et al., 1994; Carlezon et al., 1995) and 
exhibit conditioned place preference for environments where they received 
microinjections of DA agonists into the NAc, (Carr and White, 1983, 1986). However, the 
exact role of DA in reward processing per se remains controversial. Early studies posited 
that DA regulates the hedonic impact of a stimulus (Wise, 1985; Koob and Le Moal, 
1997), though that hypothesis has since been proven unlikely (Berridge et al., 1989). 
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Recent empirical evidence supports a role for subcortical DA transmission in 
reinforcement learning and attribution of incentive salience, or “wanting”, towards effort-
worthy goals (Berridge, 2012). Interestingly, exposure to unconditioned novel stimuli in 
rats transiently elevates NAc DA and triggers investigatory activity (Rebec et al., 1997; 
Legault and Wise, 2001). Similarly, consumption of a novel food, but not a familiar food, 
produces robust increases in NAc DA release in the rat (Bassareo and Di Chiara, 1997; 
Gambarana et al., 2003). Thus, some have argued that NAc DA promotes exploratory 
behaviors that aid in the formation of new motivational connections between salient 
stimuli and environmental cues (Ikemoto and Panksepp, 1999). In contrast, the findings 
reported in this thesis research propose an alternative role for NAc DA in the processing 
of unconditioned versus conditioned stimuli in mice.  
 The data presented in Chapter 2 established that repeated exposure to palatable 
food in a familiar feeding environment is necessary for the acquisition of stable 
conditioned approach behavior and the food-evoked DA response in the NAc. The 
majority of animals that were naïve to the food reward failed to approach or consume the 
food within the fifteen-minute time frame. Furthermore, in comparison to animals familiar 
with the food reward, naïve mice exhibited more signs of active avoidance, such as 
increased burying and freezing during food presentation. Lastly, animals that were 
familiar with the food, but received the food in an unconditioned feeding environment 
displayed attenuated NAc DA release and slightly increased (though not reaching 
significance) approach latencies compared to those receiving the food reward in a 
familiar feeding environment. Altogether, these findings highlight the importance of 
environmental context in the acquisition of conditioned approach behavior and 
neurochemical response to rewards in the mouse.  
 These studies also revealed important species differences in the role of the 
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mesolimbic DA system in the processing of predictive cues. In rats, anticipatory cues 
reliably promote DA release in the NAc across laboratories, whereas reports of 
increased DA release to actual consumption of the food reward have been variable 
(Cenci et al., 1992; Salamone et al., 1994; Martel and Fantino, 1996; Hajnal and 
Norgren, 2001). Consistent with the rat literature, mice exhibited a robust increase in 
NAc DA efflux when presented with an empty food dish (predictive stimulus) after being 
trained to expect the presentation of food. This finding is in accordance with classical 
Pavlovian conditioning theory, which theorizes that a neutral stimulus associated with a 
conditioned stimulus can become a conditioned stimulus in and of itself as it acquires the 
ability to elicit a conditioned response. Interestingly, the time course for DA response to 
the conditioned and predictive stimulus deviated. When presented with the food, animals 
displayed elevated DA efflux that persisted throughout the period of food presentation 
and after the food had been removed. In contrast, when presented with the empty food 
dish, animals displayed a rapid rise in NAc efflux that quickly returned back to baseline. 
Thus, DA transmission in the NAc potentially serves both as an anticipatory cue and 
consummatory cue, with the latter possibly encoding reinforcement learning for 
subsequent exposures.  
Stress as an inhibitor of incentive salience 
 
Approach-based behavioral adjustments to salient stimuli are considered one of the 
more rudimentary and elemental components of goal-directed behavior (Lewin, 1935; 
Schur and Ritvo, 1970; Elliot et al., 2006). Thus, perturbation of the neural mechanisms 
that regulate the manifestation of incentive salience likely results in dysfunctional 
behavioral output. Previous studies in rats have demonstrated that exposure to chronic 
mild stress blunts NAc DA response to palatable food (Di Chiara and Tanda, 1997; Di 
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Chiara et al., 1999; Gambarana et al., 2003). The authors concluded that reduced DA 
responsiveness to the food reward denotes an anhedonic state. Yet, stressed rats 
showed similar approach latencies and food consumption to non-stressed animals. It is 
possible that these animals had become so overtrained to the food stimulus that DA 
transmission signaling the presence of an anticipatory cue was no longer necessary to 
initiate approach behavior. Indeed, it has been suggested that NAc DA transmission is 
not necessary for previously learned behaviors or habits but may be more important for 
new learning (Ikemoto and Panksepp, 1999). Nonetheless, a lack of notable change in 
behavior in these studies makes it difficult to interpret how diminished NAc DA response 
influences motivational salience. To address the question of whether disruption of NAc 
DA transmission impairs incentive salience we employed a hyponeophagia-based 
paradigm in which conditioned approach behavior for palatable food is suppressed by an 
acute environmental stressor. We observed that presentation of a bright light and novel 
scent during food exposure blunted NAc DA reactivity to the conditioned food stimulus 
and increased approach latency without affecting the amount of food consumed. The 
fact that stressed animals do eventually approach and consume comparable amounts of 
food to non-stressed animals lends support to the hypothesis that conditioned approach 
behaviors are not dependent on NAc DA transmission. However, the delay in initial 
approach likely reflects alterations in DA mediated incentive salience. For example, DA 
may amplify appetitive behavioral states to more readily engage motor systems involved 
in approach behavior. Thus, in the absence of DA response, animals are not as 
immediately energized towards salient stimuli. Alternatively, suppression of DA response 
may alter the valence of a stimulus so that it no longer elicits “wanting”. Further studies 
are needed to dissociate these mechanisms.  
 It is important to note that both appetitive and aversive stimuli evoke activation of 
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NAc DA (Abercrombie et al., 1989; Salamone, 1994; Kalivas and Duffy, 1995). However, 
recent studies have demonstrated that distinct anatomical regions within the NAc are 
differentially modulated depending on the context of the stimuli. Lammel et al. (2011) 
demonstrated that rewarding experiences selectively modify excitatory synapses on 
dopaminergic cells projecting to the NAc medial shell, whereas aversive stimuli modify 
synapses on DA neurons projecting to the mPFC. Similarly, corticolimbic glutamate 
signals within the NAc generate appetitive or fearful behavior depending on rostrocaudal 
location with the medial shell (Faure et al., 2008). Thus, stress exposure during the 
presentation of food might selectively activate a distinct circuitry involved in processing 
of aversive stimuli while suppressing signaling pathways associated with motivational 
salience.  
A role for the mu opioid receptor in mediating incentive salience and stress 
 
One of the more striking findings of Chapter 2 is that pretreatment with buprenorphine 
(BPN), a mixed-opioid drug currently in development for the treatment of depression and 
anxiety, prevented the stress-induced suppression of NAc DA and restored approach 
latencies to that seen in non-stressed animals. These data complement previous studies 
conducted in our laboratory showing that acute BPN treatment reduces approach 
latencies in the NIH test (Falcon et al., 2015), and suggest a role for opioid systems in 
mitigating the aversive effects of stress on incentive salience for natural rewards. This 
hypothesis was explored further in Chapter 3 by probing the role of individual opioid 
receptors in mediating BPN’s effect on approach behavior in the NIH test.  
 Buprenorphine is a partial agonist at the mu opioid receptor (MOR) and an 
antagonist at the kappa opioid receptor (KOR). Accumulating evidence has linked the 
KOR and its endogenous ligand dynorphin to the negative consequences of stress in 
	  142	  
	  
rodents. Acute administration of KOR agonists induces anxiogenic and prodepressive 
behaviors in rodents (Maisonneuve et al., 1994; Carlezon et al., 2006; McLaughlin et al., 
2006), whereas treatment with KOR antagonists has been shown to elicit antidepressant 
life effects (Mague et al., 2003; Carr et al., 2010; Almatroudi et al., 2015; Falcon et al., 
2015; Huang et al., 2016). Recent studies from our laboratory have confirmed the KOR 
as a key mediator of BPN’s effects in tests with predictive validity for antidepressant 
efficacy, such as the forced swim test (FST) (Falcon et al., 2016). Therefore, we 
originally hypothesized that BPN’s effects in the NIH test are primarily derived from 
antagonism at the KOR. However, the work presented in Chapter 3 proved this 
hypothesis to be incorrect. We observed that BPN’s effects in the NIH test was 
conserved in KOR knockout animals, but abolished in MOR knockout mice. Moreover, 
administration of selective KOR antagonist nor-BNI in wildtype mice was ineffective in 
reducing approach latencies. The discrepancies between previous findings and those 
reported here are unclear. It is possible that inherent strain differences dictate response 
to KOR antagonists in this paradigm- the present work is the only of our knowledge to 
test the effects of the selective MOR antagonist cyprodime and the selective KOR 
antagonist nor-BNI in the NIH test using the C57BL/6 mouse strain. The discrepancies 
may also be due in part to differences in procedural definitions of “approach” in the NIH 
paradigm. For example, some groups might consider investigatory sniffing or licking as 
approach, whereas we took a more conservative determining of approach. To this end, 
KOR antagonism may reduce latency to investigate but not to consume. Alternatively, in 
our experiments KOR antagonism may have increased exploratory behavior rather than 
restoring incentive salience for the food reward. Indeed, KOR antagonists have 
previously been shown to increase exploratory behaviors in the elevated plus maze and 
open field (Knoll et al., 2007; Bruchas et al., 2009; Wiley et al., 2009; Wittmann et al., 
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2009).  
 Chapter 3 of this thesis established a novel role for modulation of the MOR in 
restoring approach behavior in the NIH test. Given the role of MOR in mediating the 
reinforcing properties of rewards, we predicted that BPN’s agonist action at MOR might 
underlie its behavioral effects. However, several points of evidence contradict this 
original hypothesis. Pharmacological blockade of MOR and KOR with the nonselective 
opioid receptor antagonist naltrexone did not abolish BPN’s effects in the NIH test. 
Furthermore, administration of morphine alone was not effective in altering suppressed 
approach behavior. On the contrary, acute antagonism of MOR was sufficient to reduce 
approach latency in the NIH test. This observation suggests that MORs may facilitate 
prodepressive behaviors under stressful situations. Stimulation of MORs induces 
activation of the hypothalamic-pituitary-adrenal (HPA) axis (Kiritsy-Roy et al., 1986; 
Pechnick, 1993). Moreover, CRF significantly enhances the release of β-endorphin and 
dynorphin from the hypothalamus in vitro (Nikolarakis et al., 1986). In contrast, MOR 
knockout mice exhibit less stress-induced increases in plasma corticosterone 
concentrations and reduced anxiety and depressive-like behavior in the elevated plus 
maze and FST, respectively (Filliol et al., 2000; Ide et al., 2010). Consequently, 
antagonism of MORs during stress exposure may prevent the manifestation of affective 
behavior. Notably, studies in healthy human populations have indicated that low doses 
of BPN enhance attention for positive emotional cues and reduce sensitivity to fearful 
cues (Ipser et al., 2013). Moreover, a recent clinical trial testing the efficacy of 
buprenorphine combined with a MOR antagonist revealed significant antidepressant 
activity in treatment resistant MDD patients (Ehrich et al., 2015).   
 Antagonism of MORs during stress exposure may restore incentive behavior in 
the NIH paradigm via disinhibition of mesoaccumbens DA transmission in response to 
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stress. Stress-induced activation of MORs in the ventral tegmental area (VTA) has been 
shown to reduce DA transmission in the NAc through enhanced DA signaling in the 
medial prefrontal cortex (mPFC) (Latagliata et al., 2014). This is consistent with previous 
findings establishing that in response to an acute stressor, mice of the C57BL/6 inbred 
strain exhibit a robust and rapid activation of mesocortical DA release that is 
accompanied by inhibition of DA release in the accumbens (Ventura et al., 2002).  
Recent studies indicate that activation of VTA DA neurons is differentially modulated by 
input-specific circuits. Lammel et al. (2012) demonstrated that laterodorsal tegmentum 
(LDTg) neurons predominantly synapse on DA neurons projecting to the NAc lateral 
shell and produce conditioned place preference when activated, whereas neurons 
originating from the lateral habenula (LHb) synapse primarily on DA neurons projecting 
to the mPFC and produce conditioned place aversion. Thus, aversive experiences  
appear to selectively activate DA neurons projecting to the mPFC.  Acute exposure to 
stress or administration of glucocorticoids also produces robust increases in extracellular 
glutamate levels preferentially in the PFC (Moghaddam, 1993; Bagley and Moghaddam, 
1997; Popoli et al., 2012). Stress-induced enhancement of basal glutamate transmission 
is mediated by increased expression of postsynaptic NMDA and AMPA receptors (Yuen 
et al., 2009; Yuen et al., 2011). Activation of D1 receptors in the mPFC increases 
excitability of glutamatergic pyramidal cells (Tseng and O'Donnell, 2004), which have 
been shown to project to the NAc (Carr et al., 1999). Optogenetic activation of 
glutamatergic projections in the mPFC suppresses striatal response to DA and 
diminishes the reinforcing effects of midbrain DA neuron stimulation (Ferenczi et al., 
2016). This effect may be mediated by stimulation of GABAergic medium spiny output 
neurons in the NAc (Sesack and Pickel, 1992). Thus, MOR-induced potentiation of 
mPFC dopamine activity in response to stress may lead to blunted mesoaccumbens DA 
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release in the mesolimbic pathways, and consequently, diminished incentive behavior in 
response to rewards.  Alternatively, intra-VTA LHb axonal stimulation has been shown to 
inhibit VTA DA neurons projecting to the NAc via increased GABAergic signaling from 
the rostromedial tegmental area  (RMTg) to the VTA (Lammel et al., 2012). Activation of 
MORs expressed on GABAergic neurons in the RMTg putatively increase VTA DA 
activity (Matsui and Williams, 2011). However, recent studies have revealed that 
GABAergic afferents to dopamine neurons exhibit projection specific sensitivity to 
opioids. Specifically, MOR activation induced inhibition of inhibitory postsynaptic currents 
(IPSCs) evoked from the RMTg but not VTA interneurons (Matsui et al., 2014). These 
findings suggest that opioid-dopamine interactions in the VTA are likely regulated by 
complex local circuitry. Indeed, there is evidence that local administration of MOR 
antagonists into the VTA can increase striatal dopamine concentrations (Devine et al., 
1993). LHb neurons are known to be excited by the absence of an expected reward 
(Hikosaka, 2010), however, both central administration of CRF and exposure to acute 
stress increases c-fos activation in the habenula, indicating that this region is also 
activated during stress response (Imaki et al., 1993). Thus, presentation of aversive 
stimuli with rewarding stimuli may override activation of reward-processing pathways 
and subsequent DA release in the NAc by enhancing GABAergic signaling in the VTA. 
Accordingly, acute stress exposure has been shown to increase firing of GABAergic 
neurons within the VTA (Tan et al., 2012). Future studies are needed to fully elucidate 
the role of MORs within this circuitry.    
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FIGURE 5.1 
 
 
Hypothetical mechanism of action for MOR mediated suppression of NAc DA by 
stress. Exposure to stress results in the release of stress hormones (denoted by dashed 
line) and B-endorphins. Activation of VTA MORs preferentially enhance dopaminergic 
signaling in the PFC. Glutamatergic signals from the habenula selectively activate VTA 
neurons projecting to the PFC and inhibit VTA DA neurons projecting to the NAc via 
activation of GABAergic neurons in the RMTg. The PFC exerts top-down control of NAc 
DA activity through dense glutamatergic input to inhibitory GABA neurons that project to 
the NAc. Collectively, this circuitry results in reduced DA activity in the NAc and blunted 
incentive behavior towards rewarding stimuli. 
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Stress as a facilitator of antidepressant response 
 
Whereas Chapters 2 and 3 of this thesis reflected on how stress impairs reward circuitry 
and associated motivational behaviors, Chapter 4 proposes a distinctive role for the HPA 
stress axis in sensitization of behavioral and neurogenic responses to selective 
serotonin reuptake inhibitors (SSRIs), the most commonly prescribed medication for the 
treatment of depression. Previous studies have reported the NIH test to be sensitive to 
the antidepressant effects of chronic, but not acute, treatment with SSRIs (Bodnoff et al., 
1988; Bodnoff et al., 1989; Dulawa et al., 2004; Dulawa and Hen, 2005; Bechtholt et al., 
2007; David et al., 2009). However, studies conducted in our laboratory (Balu and Lucki, 
2009) and others (David et al., 2009) have revealed strain dependent responses to 
chronic fluoxetine treatment in the NIH test, showing C57BL/6 mice, in particular, to be 
unresponsive to fluoxetine’s effects. The absence of behavioral response to fluoxetine in 
this mouse strain may parallel the phenomenon of treatment resistance seen in human 
depression (Nemeroff, 2007). We utilized the intrinsic SSRI-insensitivity characteristic of 
C57BL/6 mice to investigate strategies for enhancing behavioral sensitivity to this class 
of antidepressants in the NIH paradigm.  
 Hypercortisolism and dexamethasone insensitivity are among the most 
consistent pathophysiological findings in depression (Pariante and Miller, 2001; Pariante, 
2006; Anacker et al., 2011). Elevated basal cortisol levels are thought to arise from 
dysregulation of inhibitory feedback signals to the HPA axis and contribute to affective 
behavior. The deficit of negative cortisol feedback is restored in depressed patients after 
successful therapeutic treatment with antidepressant drugs (Holsboer et al., 1982).   
Accordingly, animals genetically modified to exhibit reduced forebrain corticosteroid 
	  148	  
	  
receptor expression demonstrate elevated CORT levels, hypersensitivity to stressors, 
and depressive-like behavior (Ridder et al., 2005; Berger et al., 2006).  
The studies in Chapter 4 employed an endogenous CORT exposure paradigm to 
examine the influence of dysregulated HPA axis activity on antidepressant response to 
chronic fluoxetine treatment in the NIH test. Notably, our chosen method of CORT 
exposure (subcutaneous pellet) was ineffective in maintaining persistently elevated 
CORT levels, and instead released a large bolus of CORT that rapidly diminished over 
the thee week treatment period. Nonetheless, we observed a marked behavioral 
response to fluoxetine treatment in the NIH test in animals previously exposed to CORT. 
Glucocorticoids have been reported to increase the salience of pleasurable or 
compulsive activities. Thus, CORT exposure may prime neurochemical pathways 
associated with motivational processing (Dallman et al., 2003). However, animals 
exposed to CORT and treated with vehicle did not exhibit reduced approach latencies in 
the NIH, suggesting a synergistic interaction between CORT-mediated sensitization and 
serotonergic signaling in this paradigm. A potential mechanism for this synergistic effect 
may lie in modulation of 5-HT receptor activity. Exposure to chronic mild stress has been 
shown to desensitize 5-HT1A autoreceptors in the dorsal raphe (Lanfumey et al., 1999). 
Activation of 5-HT1A autoreceptors inhibits serotonin release and subsequent 
postsynaptic 5-HT1A receptor activity (Hensler et al., 2007; Lanfumey et al., 2008). Thus, 
reduced presence of 5HT1A autoreceptors after CORT exposure may enhance the 
therapeutic effects of chronic treatment with fluoxetine by boosting increased 
extracellular serotonin levels in forebrain regions.  In accordance with this, a small 
clinical study conducted in the late 1990s found that dexamethasone therapy 
significantly enhanced antidepressant response to SSRIs in treatment resistant patients 
(Dinan et al., 1997).  
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 In Chapter 4 we also showed that reduced novel arena approach latency in 
CORT and fluoxetine combination treated animals was associated with a robust increase 
in hippocampal neurogenesis. Stress exposure is more commonly reported to reduce 
hippocampal cell proliferation in rodents (Cameron and Gould, 1994; Wong and Herbert, 
2004; Bilsland et al., 2006; Murray et al., 2008; Brummelte and Galea, 2010). However, 
other groups have reported augmented cell proliferation in animals exposed to CORT 
and treated with fluoxetine (David et al., 2009). Several groups have reported that 
neurogenesis-dependent mechanisms are responsible for the behavioral response to 
fluoxetine in the NIH test (Santarelli et al., 2003; Sahay and Hen, 2007; Surget et al., 
2008; Wang et al., 2008; David et al., 2009). In humans, reduced hippocampal volume is 
associated with untreated recurrent depression (Sheline et al., 1996; Bremner et al., 
2000; Colla et al., 2007) but not treated depression (Sheline et al., 2003), suggesting 
that successful antidepressant treatment can exert critical neuroprotective effects 
against chronic stress. Whether reduced hippocampal volume in humans reflects 
reduced cell proliferation or other morphological processes is controversial. 
Nonetheless, general hippocampal dysfunction is likely to play a role in motivational 
processes, seeing as hippocampal synaptic input to the NAc has been shown to mediate 
the cognitive functions necessary for initiating goal-directed behavior (Goto and Grace, 
2005).   
Concluding remarks 
 
This dissertation work has employed a unique and innovative approach to elucidating 
mechanisms underlying conditioned approach behavior for natural rewards, an RDoC 
construct relevant to the human condition. The focus on a single behavioral paradigm 
enabled the methodical assessment of neurochemical and neuropharmacological 
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mechanisms specific to stress-induced changes in incentive behavior, thus delivering 
new insight into the interactions between brain stress and reward circuitry. The findings 
presented here further expand our understanding of the neural correlates of motivation 
and propose novel targets for the treatment depression and other psychiatric disorders 
characterized by of anhedonia.  
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